H E A LT H C A R E:

ITALY ON THE MOVE

Business opportunities
in Italian Life Sciences
Selected companies and clusters

In collaboration withASSOBIOTEC

Associazione nazionale per lo sviluppo
delle biotecnologie

Business opportunities
in Italian Life Sciences
Selected companies and clusters

INDEX
LIFE SCIENCES IN ITALY: FACTS & FIGURESCOMPANIES............................................................................ V...............................................................................................

INVESTMENT OPPORTUNITIES......................................................

1
1

ALTHEIA SCIENCE ............................................................................................................................... 2
CORION BIOTECH ................................................................................................................................ 3
ENDOTICS - ERA ENDOSCOPY ...................................................................................................... 4
EXOSOMICS ............................................................................................................................................ 5
GENENTA SCIENCE ............................................................................................................................. 6
GENEXTRA .............................................................................................................................................. 7
ITEL TELECOMUNICAZIONI ............................................................................................................. 8
LIQUIDWEB/BRAINCONTROL ........................................................................................................ 9
MICROBIOTECH .................................................................................................................................. 10
MOLMED .................................................................................................................................................. 11
OTECH INDUSTRY ............................................................................................................................... 12
SILK BIOMATERIALS .......................................................................................................................... 13

STRATEGIC PARTNERSHIPS........................................................

15

A. MENARINI ......................................................................................................................................... 16
ALFASIGMA ........................................................................................................................................... 17
ANGELINI ACRAF ................................................................................................................................ 18
BIOTECHWARE ................................................................................................................................... 19
BIOTECNOMED .................................................................................................................................. 20
CHIESI FARMACEUTICI ..................................................................................................................... 21
DOMPÉ FARMACEUTICI ................................................................................................................... 22
DOPPEL FARMACEUTICI ................................................................................................................. 23
EPYGON ITALIE ................................................................................................................................... 24
FLAMMA GROUP ................................................................................................................................ 25
IQVIA SOLUTIONS ITALY ................................................................................................................. 26
ITEM OXYGEN ...................................................................................................................................... 27
KEDRION ................................................................................................................................................ 28
LABORATORIO FARMACEUTICO C.T. ........................................................................................ 29
MEDIOLANUM FARMACEUTICI ................................................................................................... 30
PANOXYVIR ........................................................................................................................................... 31
PETRONE GROUP .............................................................................................................................. 32
RECORDATI ........................................................................................................................................... 33
SOFAR .................................................................................................................................................... 34

CLUSTERS...............................................................................................

APULIA ...................................................................................................................................................
FRIULI VENEZIA GIULIA .................................................................................................................
LOMBARDY ..........................................................................................................................................
PIEDMONT ............................................................................................................................................
TRENTINO ............................................................................................................................................
TUSCANY ..............................................................................................................................................

37
38
40
42
46
48
50

LIFE SCIENCES IN ITALY:FACTS & FIGURES
1.

1st pharma manufacturer in the EU, with a production value ofover € 31 bn in 2017, +4% vs 2016, also thanks to the quality of the
supply and services chain.

2.

Largest pharma export growth in Europe: from 2007 to 2017+107% (vs +74% big European Countries average).

3.

€ 1.5 bn pharma R&D investments in 2017, grown by 22% overthe last 5 years (vs +16% the European average), with an everincreasing synergy between companies and public bodies.

4.

€ 700 m invested yearly in clinical trials by pharma companies,
rising to € 1 bn if we include medical devices companies.

5.

65,400 highly qualified employees (90% with secondary school
certification or university degree) with 6,000 new jobs in 2017.
A skilled and flexible workforce is considered a crucial factor byforeign companies who have already located in Italy.

6.

Top destination for life sciences FDIs in Europe: 60% of pharmacompanies based in Italy are foreign-owned companies.

7.

Vibrant pharma national industry, doubling its export value overthe last 10 years.

8.

Robust medical devices sector, accounting for over 3,800
companies and hosting the “Mirandola district”, one of the top
biomedical clusters in the world.

9.

3 out of 6 advanced therapy medicinal products currently
authorized for the EU market are the result of Italian R&D.

10.

Therapeutic pipeline of 314 biotech projects, of which 90 in clinicaldevelopment.

11.

World-class R&D in a wide range of areas, including vaccines,
oncology, neurological and degenerative diseases, immunology,
rare diseases, plasma derivatives, respiratory and cardiovasculardiseases.

12.

World-renowned National Healthcare System with universal
coverage, including a wide range of excellent institutes as potential
partners (the overall healthcare sector accounts for 11% GDP).

v

COMPANIESINVESTMENTOPPORTUNITIESParticipating Company

ALTHEIA SCIENCE
Description

Focus

Investment opportunities

Altheia Science develops a gene therapy-based approach in Type I diabetes andmultiple sclerosis that aims at reverting the root cause of the disease, by ex vivo
lentiviral vector-transducing autologous hematopoietic stem and progenitor cells(HSPC) to reconstitute PD-L1 expression. Re-inoculation of modified HPSC should
entail the establishment of a correct balance in controlling immune responses, bypromoting a tolerogenic effect triggering the PD-1/PD-L1 axis with the result to
exhaust auto-reactive T lymphocytes effector capabilities, thus preventing autoimmune reactions against self-antigens. The approach has the potential to betransformative in the management of autoimmune diseases.

Products• ImmunoStem for T1D - Stage of Development: PreclinicalArea of Activity
Medical research

Foundation
12/1/2017

Company size
Employees
From 3 to 9 employees
TurnoverLess than 75.000 Euro

InfoHeadquarter

Via Enrico Besana 7, Milano
www.altheiascience.com• ImmunoStem for MS - Stage of Development: PreclinicalTechnology and Patents
Altheia Science has an exclusive worldwide license from the Children’s Medical
Center Corporation (CMCC) of 3 patent families for the treatment and preventionof autoimmune diseases and cancer, including PD-L1 expressing hematopoietic
stem cells and uses, composition and methods for treating diseases anddisorders of the central nervous system (non-exclusive), and the discovery of themiRNAs network controlling PD-L1 expression (unpublished, at US Provisional
state).
Patent Office and filing dates:
a. PCT/US2016/043053, filing date 20.07.2016, priority data 62/194969 21.07.2015 US
b. PCT/US2017/056774, filing date 16.10.2017, priority data 62/408664 14.10.2016 US
c. Unpublished patent, at US Provisional state

Key opportunities
Preferred Partner: FinanceThe capital raise is presently ongoing with a target of €15M.

Key Contact

Subscribed capital: €9.3M.

Paolo Rizzardi
Chairman&CEO

Altheia Science, exploiting the scientific and management expertise of thecompany, intends to promote the product development at international level,
not only in Italy but also in Europe and in the USA. Product development
includes the execution of IND-enabling studies focused on the demonstration ofa favorable benefit/risk ratio, on safety and on the design of appropriate clinicaldevelopment plans. Finance partners in the USA would favor the enablement of
this process.

paolo.rizzardi@altheiascience.com+39 335 19 35 042

Gabriele Campi
Project Manager
gabriele.campi@altheiascience.com+39 320 06 73 899

Other opportunities
Additional opportunities come from the establishment of partnerships with othercompanies in the field to exchange technologies and foster the execution of
Altheia Science programs.
Target Market: The target market includes new cases of Type I Diabetes andpatients with Relapsing-Remitting Multiple Sclerosis. Altheia Science is focusedon the first clinical demonstration of safety and efficacy of these innovative
approaches, including innovative drug products and routes of administration.

2

CORION BIOTECH
Description
Corion Biotech was founded in 2012 by A. Rolfo, T. Todros, C. Cavallero, E. Piccoli.
CB project originates from over 2 decades of translational research in the fields ofhuman placenta physio-pathology.

Focus

Investment opportunities

Two biological drugs originated from this research:
CB-ChMF-11 demonstrated strong immunomodulant, anti-inflammatory andproangiogenic action on the preeclamptic placental tissue both in vitro and in vivo ina preeclampsia (PE) animal model, leading to the resolution of PE clinical culprits.
CB-ChMF-12 demonstrated strong in-vitro selective anti-angiogenic, proinflammatory and profibrotic actions on epithelial cancer cells inducing fibrotizationof tumoral tissues and metastasis inhibition.

Products

Area of Activity
Pharmaceutics

Foundation
12/6/2012

Company size
Employees
Less than 3 employees
TurnoverLess than 75.000 Euro• CB-ChMF-11 - Stage of Development: regulatory preclinical study, based on
EMA scientific advice.
• CB-ChMF-12 - Stage of Development: PoC on recognized animal model.

Technology and Patents
Title: “A conditioned medium obtained from placental mesenchymal cells and useof thereof for the therapeutic treatment of Preeclampsia.”
Priority: 21/12/2011
Application NO: PCT /IB 2012/057611
Status:• Granted in EU (28 countries)• Pending in USA, Japan, CanadaThis patent covers preparation and therapeutic application of CB-ChMF-11

Info
Headquarter

Via Gioacchino Quarello 15/A,
Torinowww.corionbiotech.com
Key Contact

Title: Preeclamptic placental mesenchymal stem cell conditioned medium for use
in the treatment of a tumour
Priority: 02/10/2012
Application NO: PCT/IB2013/059064
Status:• Granted EU, USA, Japan• Pending China, Canada

Carlo Cavallero
CEO

This patent covers preparation and therapeutic application of CB-ChMF-12

carlo.cavallero@corionbiotech.com+39 3474997277

Key opportunities

Alessandro Rolfo
CSO

Subscribed capital: €600K

alessandro.rolfo@corionbiotech.com+39 3886447730

Preferred Partner: Finance
Shareholders:• Alessandro Rolfo 24,75%• Tullia Todros 24,75%• Carlo Cavallero 24,75%• Ettore Piccoli 0,75%• IP Investimenti & Partecipazioni 25%
Preeclampsia is currently an unresolved medical need with enormous medical
and financial impact. Based on epidemiology, this new therapeutic approach
could generate a turnover of 3 to 5 billions of euro just in developed markets.
Epithelial tumors are among the most common and frequent neoplasms. The
evidence of Cb-ChMF-12 biological activity suggests an application as a presurgery treatment.

3

Participating Company

ENDOTICS - ERA ENDOSCOPY
Description

Focus

Investment opportunities

Endotics is in the business of developing, producing and marketing medical
devices and primarily the Endotics System, a Self Propelling Robotic Colonscope.
The Company believes that the Endotics System will revolutionize the way
physicians carry out endoscopy procedures. The Endotics System allows for apainless, easy, safe procedure for the entire colon (from anus to ceacum). Itsinnovative technology removes any risk of cross- contamination and perforation
during the endoscopy procedure.
The Company seeks to develop medical devices that will revolutionize the way
to make diagnosis and biopsy, drugs dosage and surgery thanks to micro robots
which travel in the human body.

Products

Area of Activity
Medical devices

Foundation
12/1/2016

Company size
Employees
From 10 to 19 employees
TurnoverFrom 250.000 to 750.000
million Euro

InfoHeadquarter

Cascina via Cava 28, Pisa
www.endotics.com
Key Contact

Giuliano Gorini
President & CEO
giuliano.gorini@yahoo.it+39 345 571 261 32

Ilaria Baldi
CFO
amministrazione@endotics.com

4

The Endotics System comprises a work station and a robotic colonscope. The
work station is a control box through which the physician records the film anddrives the robot using a plugged in joystick.
At time being the product is ready for screening market. Currently iscommercialized in Italy by one sales rep. Italian distribution channel is underdevelopment. International partners are going to deliver distributions businessplan proposal.
The robotic colonscope is an innovative disposable tool which, thanks to its
swinging capabilities, allows the physician to explore the entire colon by driving
it through the human body. It is not a system of pushed-through technology.
The micro robot moves back and forth thanks to a mechanical distinguishingquality covered by three international patents (self propelling technology). The
materials used are totally disposable, soft and smooth, removing any risk of Cross
Contamination and Perforation while at the same time minimizing the Discomfort
to patients. Direct Vision reduces error chances (false positive / false negative),thanks to a camera placed on top of the robot and its steering capability whichallows physician to explore the colon very accurately.

Key opportunities
Preferred Partner: Finance / Distribution & Trade

EXOSOMICS
Description

Focus

Investment opportunities

Exosomics develops and commercializes solutions for liquid biopsy. In particular,
it has developed and just launched immuno-affinity solutions that can isolate
tumour-derived exosomes, from which DNA and RNA can be extracted. These inturn are the substrate of any analytical assay aimed at detecting cancer relevant
mutations. The advantage of this solution is that it enriches for tumour-derived
material, resulting in better performing analytical assay and therefore earlier
cancer detection and ultimately better patient outcomes.

Products• SeleCTEV - Stage of Development: launched.
• SoRTEV - Stage of Development: launched.
• ExoRef - Stage of Development: Next to launch.

Area of Activity
Diagnostic IVD

Foundation
1/1/2012

Company size
Employees
From 10 to 19 employees
TurnoverFrom 75.000 to 250.000 Euro

InfoHeadquarter• End-to-end line of products - Stage of Development: Optimisation /Validation.
Exosomics technology is based on immuno-affinity reagents to capture tumouderived exosomes. The portfolio of IP - patents and licenses - covers both themethods to capture tumour-derived exosomes and the biomarkers involved.

Key opportunities
Preferred Partner: FinanceExosomics is opening a Round A of investment to support the growth of thecompany. In particular to expand commercial operations in the US and expand
the portfolio of next generation liquid biopsy solutions.
Subscribed capital: €7.5M

Other opportunities
Partnering with IVD providers.

Str del Petriccio e Belriguardo
35, Siena
www.exosomics.itKey Contact

Andrea D’Ambrgoio
Head of Business
Development
adambrogio@exosomics.eu+39 328 200 90 80

Antonio Chiesi
CEO
achiesi@exosomics.eu+39 349 292 13 69

5

Participating Company

GENENTA SCIENCE
Description

Focus

Investment opportunities

Genenta develops a lentivirus ex-vivo gene transfer strategy into autologous
hematopoietic stem/progenitor cells (HSPCs) to target interferon-expression totumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs).
As a result, a recruitment of tumor-specific cytotoxic Tcells is added to theinterferon-effect.
Genenta has been authorized to enter in a Ph I/II clinical trials in early Multiple
Myeloma relapsing and newly diagnosed Glioblastoma tumor patients. Enrollment
will start in Jan 2018.

Products• TEMferon - I/O via GT - Stage of Development: clinical stage (PhI/II).

Area of Activity
Pharmaceutics

Foundation
7/24/2018

Company size
Employees
From 3 to 9 employees
TurnoverLess than 75.000 Euro

InfoHeadquarter

Via Olgettina 58, Milano
www.genenta.com
Key Contact

Pierluigi Paracchi
Chairman & CEOpierluigi.paracchi@genenta.com+39 335 73 51 868

Carlo Russo
Chief Medical Officer
carlo.russo@genenta.com

6

Technology and Patents
Immuno-Gene Therapy for Tumor Treatment
Using a combination of transcriptional and microRNA-mediated control, TEMs
become capable to selectively express interferon-limited to the tumormicroenvironment.
Based on these mechanisms, TEMs are armed with a specific drug and cansystematically break the tumor immune-tolerance reprogramming the microenvironment and generate an immune response.
In contrast to antigen-restricted Chimeric Antigen Receptor T-cells (CAR-T),
TEMferon generates immune responses to anyTEMs positive tumors.

Key opportunities
Preferred Partner: Finance
Genenta raised $20 Million (Euro 17M) Series A+B Round of financing in March
2015 and September 2017.
Series C Round of Financing, target $25M.

Participating Company

GENEXTRA
Description
Genextra is an investment company.
As a holding it provides financial and managerial support to its subsidiaries while
they focus on science, guiding their transition from a research driven entitiy to aself-standing biotech company.

Focus

Investment opportunities

Its mission is to identify innovative research in life science and to develop novel
therapies and tools by creating successful business initiatives in a sustained andlong term way.
Genextra’s holding structure is designed to increase the probability of successof business initiatives that become part of the Group by providing specialist
management as well as financial support to a new company vehicle or an existing
young start-up.

Area of Activity
Life sciences related activities

Foundation
9/19/2003

Company size
Employees
From 3 to 9 employees

Genextra was created in 2004 by a group of prominent Italian entrepreneurs andfinancial institutions in partnership with leading scientists from the European
Institute of Oncology (IEO).
To date, Genextra has raised over €116 million and represents one of very few
examples in Italy of private capital invested for the benefit of research andinnovation.

Products
Genextra is a flexible organization where subsidiaries can improve the probabilityof their success leveraging on a virtual management model with centralized skills
and resources covering all major necessities of a life sciences start-up:• Business development and management of IP• IP management support• Strategic planning

InfoHeadquarter

Via G. de Grassi 11, Milano
www.genextra.it
Key Contact• Scientific and regulatory services• Financial planning and human resources management• Public grant management

Key opportunities
Preferred Partner: Finance

Paolo Fundarò
CFO
paolo.fundaro@genextra.it+ 39 0236515111

Sonia Hardman
CFO Assistantsonia.hardman@genextra.it+39 02365111

7

Participating Company

ITEL TELECOMUNICAZIONIDescription

Focus

Investment opportunities

ITEL Telecomunicazioni®, also known as ITEL, started its business in thetelecommunications sector providing in Italy radio links and electromagnetic
shields for the information protection for the Armed Forces, NATO bases,
ENEL (National Electricity Company), banks and radio/TV networks. Thanks
to the experience and expertise acquired in electromagnetic waves, fields
and radiations, ITEL has expanded its market to include the medical, theradiopharmaceutical and the electromagnetic compatibility sectors and it has
progressively diversified its business. In 2010 Itel started the R&D for Proton
Therapy division, studying cancer therapy using proton beams.

Products

Area of Activity
Medical devices

Foundation
6/17/1982

Company size
Employees
From 50 to 99 employees
TurnoverFrom 5 to 15 million Euro

InfoHeadquarter

Via Labriola 39 ZI, Ruvo diPuglia (BA)
www.itelte.itKey Contact

Michele DiaferiaCEOm.diaferia@itelte.it+39 08 036 110 33

Leonardo Diaferia
President
leonardo@itelte.it+39 08 036 110 33

8• Erha system - Stage of Development: Linac in producing 50MeV, Robotizedpatient positioning system under development, software for TPS underdevelopment.

Technology and Patents
ERHA is the innovative Proton Therapy System for cancer treatment developedby Itel. For its realization, the company has collaborated with national research
institutions such as INFN, ENEA, University.
The system consists of three parts: Proton Linear Accelerator (LINAC) for ClinicalUse, robotic patient positioning platform and dose delivery system integrated
control and treatment planning (TPS) software.
ERHA system is linear, modular and compact, and reaching 230 MeV allows totreat deep tumors.
Patent Office and filing dates:2010 n° 101694586 - Sistema robotizzato per il posizionamento di un paziente(Robotized patient positioning system)2014 n° 2283706 – Accelerator pack, specifically for linear acceleration modules.

Key opportunities
Preferred Partner: Finance
ITEL aims to develop a partnership on a start up related on business developentof Erha protontherapy system worldwide and expecially in US market.

Other opportunities
ITEL aims to develop a partnership on a start up related on new radiation
technologies related to cancer treatment.

LIQUIDWEB/BRAINCONTROL
Description
Liquidweb is an ICT company focused on Artificial Intelligence applied to humancomputer interaction (HCI).

Focus

Investment opportunities

Liquidweb has developed BRAINCONTROL, a platform for HCI based on
biofeedback. Its first application was addressed as a breakthrough Augmentative
Alternative Communicator controlled by thoughts, for LIS/CLIS patients.
BrainControl allows people suffering from pathologies such as Amyotrophic
Lateral Sclerosis (ALS), Multiple Sclerosis, tetraplegia and various kindsof muscular dystrophies to overcome severe physical and communicative
disabilities.
The company received multiple international awards.

Products

Area of Activity
eHealth, mHealth, telemedicine

Foundation
12/16/2012

Company size
Employees
From 3 to 9 employees
TurnoverFrom 75.000 to 250.000 Euro

InfoHeadquarter

Viale Maccari 1, Siena
www.braincontrol.com
Key Contact• BRAINCONTROL AAC - Stage of Development: Ready to market.
• BRAINCONTROL IOT - Stage of Development: Prototypes, POC.

Technology and Patents
The core of the system is a classifier of signal pattern coming from wearable
biometric sensors (EEG, inertial, etc.) and/or the environment (2d and 3d
camcorders) based on a Machine Learning technology and Artificial Intelligence
for the customization of specific needs of each patient.
Patent Office and filing dates:• IT102015000052009, granted• PCT/IB2016/055442, national phases

Key opportunities
Preferred Partner: Finance, Distribution/Trade
Subscribed capital: €3M (€2.5M from Redseed)
Investments for next round financing
Market access to US/Canada

Pasquale FedeleCEOp.fedele@braincontrol.com+39 05 771 916 187

9MICROBIOTECH
Description

Focus

Investment opportunities

Microbiotech Srl is an innovative start-up founded at the end of 2013 committed
in the production and assembly of medical devices (DM) and in vitro diagnostic
medical devices (IVD) intended for use in diagnostic medicine, forensics andenvironmental analysis. Microbiotech Srl efficient manufacturing process andhigh quality attention allowed us to obtain the ISO 13485:2016 Standard Quality
System certification.

Products

Area of Activity
Medical devices

Foundation
12/16/2013

Company size
Employees
From 10 to 19 employees
TurnoverFrom 750.000 to 2.5 million Euro

InfoHeadquarter

Via Achille Tamborino snc,
Maglie (LE)www.microbiotechsrl.com
Key Contact

Ugo Masullo
QA and R&D Manager
qualita@microbiotechsrl.com

Microbiotech Srl manufactures microbial sampling products for traditional
culture analysis and molecular diagnostic assays. Its products include a complete
range of devices ready to use, suitable for the transportation and preservationof the clinical microbiological samples. The devices are able in a wide range oftype and combinations such as dry swabs, swabs with gel transport media andthe most recent swabs with liquid transport media. Devices, where applicable,
have CE certification issued by a Notified Body recognized by Accredia (theItalian Accreditation Body) in order to guarantee safety according to thestrictest national and international standards. Moreover, all devices are produced
according to GMP (Good Manufacturing Practice) and eventually in accordancewith CLSI M40-A2 (Quality Control of Microbiology Specimen Transport Devices).

Technology and Patents
The company has large space reserved exclusively for R&D activities andhas qualified personnel able to follow every single stage of new products
development, from engineering to performance evaluation. Microbiotech Srl
has recently won a very important financing project called Innonetwork inwhich it collaborates, as lead partner, with major research institutions, such as
Universities and the National Research Council (CNR), and other companies forthe development of new sampling and transport systems that will be much more
performing than those currently on the market. Moreover, with this project thecompany intends to develop two other transport systems: one user friendly able
to detect pesticides and heavy metals from food and another to be used in thelaboratory by experienced personnel for manipulations of molecular biology.
Patent Office and filing dates:
Patent n. 1354568 registered in Italy on 30/03/2014, titled “Closing system fortransport buffer”.

Key opportunities
Preferred Partner: Finance, R&D
Microbiotech Srl born as an innovative start-up so the Company has in its DNA
the research and development of cutting-edge solutions in the biomedical field.
Although collaborations with Italian companies and research institutions are
already in place, Microbiotech Srl would like to expand its range of collaborations
to potential international partners.

Other opportunities
In addition to R&D collaborations, Microbiotech Srl is interested in financiers anddistributors.

10

Participating Company

MOLMED
Description
MolMed S.p.A. is a medical biotechnology company focused on research,development and clinical validation of innovative anticancer and rare diseases
therapies.

Focus

Investment opportunities

Area of Activity
Biotech, pharmaceutical, Cell&Gene

The Company’s original dual business model is based on a growing anddiversified proprietary pipeline of products in clinical and preclinical stage withautologous and allogeneic therapies:
Zalmoxis® (TK), a patient specific cell therapy used in haploidentical transplants
already authorized for the EU market, CAR-CD44v6, in advanced preclinicalstage targeting both liquid and solid tumors, new CAR proprietary pipeline both
autologous and allogeneic, the last one based on NK (Natural Killer) cells.
MolMed also provide tailor made services for Cell & Gene therapy project, in termsof development and GMP manufacturing of clinical grade retroviral and lentiviral
vectors and genetically modified cells, for its proprietary products as well as forthird parties or in partnership in its own GMP 4,800 sqm facilities. MolMed is listedon the main market (MTA) of the Milan stock exchange, since 2008 (MLMD.MI).

research, development and manufacturing

Foundation
7/11/1996

Company size
Employees
From 50 to 200 employees
TurnoverFrom 15 to 50 million Euro

InfoHeadquarter

Via Olgettina 58, Milano
www.molmed.com
Key Contact

Ilaria Candotti
IR&Communication Manager
0221277205
ilaria.candotti@molmed.com

Maria Virginia Tonus
IR&Communication Specialist

Products• Zalmoxis® - First patient-specific cell therapy for the treatment of leukemia
and other high risk hematologic tumors in. Zalmoxis® (TK) is an ex vivo celltherapy based on donor T cells genetically engineered to enable bone marrowtransplants from partially compatible donors, inducing a rapid immune
reconstitution. Received Orphan Drug Designation and has already obtained
a Condtional Market Authorization by the European Commission as well as
reimbursement in Italy and in Germany.
• CAR-CD44v6 - An original immune-gene therapy in advanced preclinicaldevelopment, potentially effective both for some hematological malignancies
and several epithelial tumors.
• CAR therapies proprietary pipeline - MolMed is one of the few biopharma
worldwide having a diversified pipeline in both autologous and allogeneic
CARs.
• Autologous CAR-T Platform——No GvHD risk——Targeting liquid and solid tumors• Allogeneic CAR-NK Platform——CAR-NK cells are one of the most innovative pre-clinical investigations incellular immunotherapy with much less competition compared to autologous• CAR-T——NK cells exclude GvHD——Wider market potential, off the shelf therapy (1 batch = multiple patients)

mariavirginia.tonus@molmed.com

Key opportunities
Preferred Partner: Financial, Biotech, Cell&Gene investor
MolMed GMP Solutions provides tailor-made services for the development andmanufacturing of patient specific cell & gene therapies and cellular immunotherapies.
MolMed GMP Solutions offers high level expertise to develop, conduct andvalidate custom studies, optimize and scale-up manufacturing projects, devising
innovative testing procedures and addressing the unique test specifications
required for novel therapies.

Other opportunities
MolMed’s in-house GMP facility is authorised by the Italian Pharmaceutical
Agency (AIFA) for the production and release of medicinal products, andcomplies with the requirements of current legislation and best practice guidelines
for the manufacturing of patient-specific or genetically modified cells and active
pharmaceutical ingredients for clinical use.
11

OTECH INDUSTRY
Description
Development of new plasma technology with applications in human and animal
surgery and in aesthetic medicine.

Focus

Investment opportunities

Products• ONEMYTIS - Stage of Development: Entry in international veterinary market.
• ONEYONIS - Stage of Development: Certification for human market inprogress.
• ONEBEAUTY - Stage of Development: Design in progress.

Technology and Patents

Area of Activity
Electromedical and medical
equipment (non diag)

Foundation

Patented technology ionize air and allows to treat tissues at very low temperature(<50°c, <122°f) with great benefits for patient healt.
Patent Office and filing dates:
BR20151128147 - 2014-05-08
WO2017013624(A1)-2017-01-26

1/15/2013

Company size

Key opportunities

Employees
Less than 3 employees

Preferred Partner: Finance
Subscribed capital: €1.25M

TurnoverFrom 75.000 to 250.000 Euro

Through finance contribution Otech industry will be able to open international
markets and develop its new technology.

InfoHeadquarter

Via Amendola 1, Alessandria
www.otechindustry.it/enKey Contact

Franco PavignanoCEOpavignanofranco@gmail.com+39 348 151 51 07

Sisto Ghione
President
info@otechindustry.it+39 348 151 51 07

12

Participating Company

SILK BIOMATERIALS
Description

Focus

Investment opportunities

Silk Biomaterials is a regenerative medicine startup founded in 2014 by four life
sciences professionals. It raised a €7M Series A round in early 2016, following
the investment of €485k by some business angels in 2015. The proprietary
technology platform is based on pure silk fibroin and targets a wide range ofclinical needs, from regenerative medicine (vascular grafts, nerve guides, rotator
cuff repair, etc.) to drug release applications (bladder cancer).
The first application – nerve repair – has already received IRB approval andpatient recruitment will begin at the beginning of 2019.

Products

Area of Activity
Biomaterials

Foundation
7/21/2014

Company size
Employees
From 3 to 9 employees
TurnoverLess than 75.000 Euro

InfoHeadquarter

Via Cavour 2, Lomazzo (CO)www.silkbiomaterials.com
Key Contact

Gabriele Grecchi
CEOgabriele@silkbiomaterials.com+39 392 175 11 86

Antonio Alessandrino
Chief Technology Officer
antonio@silkbiomaterials.com+39 338 994 51 18

SilkBridge is our first device to enter the clinic. It’s a biocompatible silk fibroinbased scaffold, which recruits the patients’ own cells to remodel or regenerate
the nerve, without pre-seeding of the scaffold nor biological/chemicaltreatments.
SilkBridge consists of a silk fibroin scaffold with a hybrid electrospun-textile
structure in which electrospun (ES) layers, in the inner and outer parts of thedevice, are coupled to the textile (TEX) layer, in the middle. This configuration
allows the body’s natural healing process to repair the nerve while its tube shapeisolates and protects the injured nerves during the healing process.
SilkBridge is intended to repair of peripheral nerve discontinuities where gap
closure can be achieved by flexion of the extremity.

Technology and Patents
The current product portfolio is tilted towards creating positive value foreach clinical need, at different time points. The R&D focus is also dedicated toreducing regulatory risks and speeding up the approval process both in Europe
and in the US Silk Biomaterials already engaged with the FDA, through the PreSubmission program. Long-term preclinical studies are currently ongoing for thevascular graft application and we are ready to confirm in GLP settings the proof
of concept already obtained in the orthobiologic area.

Key opportunities
Preferred Partner: FinanceSilk Biomaterials is targeting a €25-30M Series B round at the end of 2019, tocomplete the clinical development of the current pipeline and pre-industrialized
its manufacturing process in GMP for the main applications (vascular & nerve).
By the end of 2021, results from our clinical studies will support market entry
of some of our products in the US – via the 510(k) route – and Europe. Current
shareholders (the VC fund Principia and business angels) will seek participationin the Series B.

13

COMPANIESSTRATEGICPARTNERSHIPSParticipating Company

A. MENARINI
Description

Focus

Strategic partnerships

The Menarini Group is one of Europe’s 15 leading pharmaceutical companies,
headquartered in Florence, Italy with Global operations powered by morethan 17,000 employees generating a turnover of €3,6 billion in 2017. Its rapid
international business expansion with more than 100 affiliates and partners,
advocates its global reach.
The focus of the privately-owned company is researching, developing,
manufacturing and marketing medications of high therapeutic value for patients.
It is committed in these key areas: oncology, anti-infectives, pain, respiratory andcardiovascular.
Menarini’s research activities are carried out throughout its 6 fully-integrated
R&D centers in Europe and Singapore in addition to 16 manufacturing plants
throughtout the globe.

Area of Activity
Pharmaceutics

Foundation
1/1/1886

Company size
Employees
More than 499 employees
TurnoverMore than 50 million Euro

Info

Products
Menarini Silicon Biosystems (MSB), based in Bologna, Italy, and Huntingdon
Valley (PA , USA), develops technologies and products that help researchers
understand the biological complexity of disease through the study of single
cells. The company mission is to develop innovative diagnostic solutions basedon single cell analysis through its technology portfolio including the DEPArray
NxT, an image-based digital cell-sorting platform, the CELLSEARCH®, theonly FDA approved Circulating Tumor Cell (CTC) enumeration System andAmpli1™ single cell genomic amplification and analysis kits . The integrationof CELLSEARCH®, DEPArray™ and Ampli1™ provides an end-to-end workflow
solution for the enumeration, isolation, and molecular characterization of CTCs
from a simple blood test in the clinical research setting, with an aim to improvethe effectiveness of precision medicine in metastatic settings. Other areas ofapplication of MSB single cell technology include primary FFPE biopsies intumors with low cellularity for a more accurate detection of genomic aberrations.
Menarini Silicon Biosystems is a wholly owned subsidiary of the Menarini Group.

Headquarter

Via Sette Santi 1, Firenze
www.menarini.com
Key Contact

Maria Sala
Corporate Licensing Director
masala@menarini.it+39 055 5680 656

Stefano Pieri
Corporate Director Licensing
and Business Development
spieri@menarini.it+39 055 5680 391

Technology and Patents
Menarini Research is in charge of all the Group’s Research and Development
activities: from the initial phases of a new project up to drug registration.
The biotechnology centre, Menarini Biotech, and the Menarini Research andDevelopment Centre guarantee the continuous development of target therapies
and define new innovative approaches to research.
Menarini is investing in major medical research projects that cover the following
therapeutic areas:• Cancer, for solid tumours and blood cancer and for support therapies• Gastro-intestinal• Analgesia

Key opportunities
Preferred Partner: Industry and R&D
Small / mid size companies not present in Europe and Asia, willing to partner
their projects.

16Participating Company

ALFASIGMA
Description

Focus

Strategic partnerships

ALFASIGMA was set-up in 2015 by merging Alfa Wassermann and SigmaTau, two international, Italy based pharmaceutical players. Based in Bologna(Italy), with 2,800 employees, ALFASIGMA has 16 subsidiaries all over theworld and authorized distributors in more than 70 countries. Through its R&D,
manufacturing capabilities and commercial units, Alfasigma markets prescription
and OTC drugs and medical foods. R&D laboratories focus mainly on thegastrointestinal area. 2017 ALFASIGMA turnover reached 1.06 Bn euro, 44% of
which is made of four internally developed, proprietary molecules one of which Normix®, Xifaxan®– through ALFASIGMA partners has reached a WW turnover inexcess of €1,3 Bn.

Products

Area of Activity
Pharmaceutics

Proprietary molecules developed in-house:• Rifaximin (Xifaxan, Normix and other brands)• Sulodexide (Vessel and other brands)• L-Carnitin (Carnitene and other brands)

Foundation
1/1/1948

Company size
Employees
More than 499 employees
TurnoverMore than 50 million Euro

InfoHeadquarter

Via Ragazzi del ‘99 5, Bologna
www.alfasigma.com

Most renowned products:• Biochetasi (product based on several components with anti-acidic anddetoxifying action, helping the restoration of cellular metabolism).
• Neo-Borocillina (antiseptic and throat disinfectant treatment).
• Dicloreum (line of self-medication products for the treatment of painful andinflammatory conditions of a rheumatic or traumatic nature of joints, muscles,
tendons and ligaments).
• Yovis (self-medication product used for the healing of slight, transient andeasily recognizable disorders. It is used in dismicrobial syndromes such as
diarrhea, non-specific enteritis and colitis. The medicine is also used in thetreatment of intestinal dismicrobism by antibiotics).

Key opportunities
Preferred Partner: R&DKey Contact

Anton Giorgio Failla
Corporate Business
Development Executive
Directorantongiorgio.failla@alfasigma.com+39 0516489721

17

Participating Company

ANGELINI ACRAF
Description
Angelini is a privately owned international group. Founded in Italy in the early
20th century, it has branches in 20 countries and employs approximately 6,000
people. The pharmaceutical sector is the core business, representing over 50% of
the Angelini group, around €1.7 billion 2017 revenue.

Focus

Strategic partnerships

Angelini pharmaceutical products are available in over 60 countries through its
branches and an extensive network of licensees and strategic agreements withlocal pharmaceutical companies.

Products
The company portfolio focuses mainly on pain relief, inflammation, CNS, and has
a strong position in the OTC market.
The most well-known international brands are:Area of Activity
Pharmaceutics

Foundation
12/19/1919

Company size
Employees
More than 499 employees
TurnoverMore than 50 million Euro

InfoHeadquarter

Viale Amelia 70, Romawww.angelinipharma.com
Key Contact

Gianluigi Maria Frozzi
Chief Executive Officer
v.coccoli@angelini.it

Serena Tongiani
Chief Scientific Officer
r.esposito@angelini.it• Trittico (trazodone, antidepressant)• Tantum (benzydamine, anti-inflammatory)• Aulin (nimesulide, analgesic - anti-inflammatory)• Vellofent (fentanyl, analgesic)• Xydalba (dalbavancin, antibiotic)• Latuda (lurasidone hydrochloride, antipsychotic)
Angelini is active in the field of self-medication with well renowned brands in the
Italian market such as Tachipirina, Moment, Tantum Verde, Amuchina.
Angelini Group launched joint ventures with Procter & Gamble in the fieldof personal care (baby diapers and sanitary napkins) and implementation of
integrated production lines for the sanitary products industry.

Technology and Patents
The topical anti-inflammatory benzydamine and the antidepressant trazodone,
are worldwide distributed and commercialized in more than 60 Countries.
Angelini in-licensed the fluoroquinolone prulifloxacin in the ‘90, and carried out
its full preclinical and clinical development in Europe, following the registrationand commercializing the product in several European countries.
More recently, Angelini strengthened the efforts in the anti-infective area by
in-licensing dalbavancin, a semi-synthetic second-generation lipoglycopeptide
antibiotic, in use for the treatment of ABSSSI (acute bacterial skin and skinstructure infections). Furthermore , the first ever in Europe combination ofparacetamol and ibuprofen just entered the Angelini portfolio.
The R&D department is currently working on several projects in the areas ofPain & Inflammation Disorders and Nervous System Diseases & Disorders. In thelatter the Angelini R&D is particularly active in developing drugs and appropriate
formulations for the pediatric population. R&D is working in discovery programs,
including private-public projects with New Chemical Entities, as well as clinicalstudies (phase I and II) and in clinical studies for already marketed products fully
developed by Angelini.

Key opportunities
Preferred Partner: R&D
Looking for R&D and BD opportunities in fit with Angelini strategy and core areas.

18BIOTECHWARE
Description

Focus

Strategic partnerships

Biotechware is an emerging company in the Connected Health & Care market.
We design and develop hardware and software solutions that can collect andtransfer clinical information coming from different sources and addressing several
information systems, keeping the information unchanged in the highest security
and data quality standards.

Products• CadioPadPro - Stage of Development: on the market.
• TensioPod - Stage of Development: on the market.

Technology and Patents

Area of Activity
eHealth, mHealth, telemedicine

Foundation
2/14/2018

Company size
Employees
From 10 to 19 employees
TurnoverFrom 250.000 to 750.000 Euro

Info

Biotechware is a cloud-based EHR system that represents a sophisticated storageof the patient’s clinical data in digital format, which are securely stored andexchanged, and accessible to various authorized users. The Biotechware platform
utilizes advanced TLS cryptographic protocols to ensure the greatest safety inthe transmission on TCP/IP networks from the source to the addressee, thus
preventing any tampering with, falsification and interception of the data.
AES algorithm with 256-bit top secret key for high security and performancelevels united to calculation speed.
SCRYPT algorithm as key deriving function based on password for the protectionof the hardware attacks.

Key opportunities
Preferred Partner: R&D
Artificial Intelligence algorithm for application in telemedecine

Headquarter

Via Cardinal Massaia 83, Torino
www.biotechware.com
Key Contact

Alessandro Sappia
CEOa.sappia@biotechware.com

19BIOTECNOMED
Description
Biotecnomed is a LLC Consortium managing the Calabrian Cluster of Innovation
for Life Sciences. It delivers services to companies in the healthcare, life scienceand biotech areas: rapid prototyping of new devices, R&D services, IP services,hosting and training services.

Focus

Strategic partnerships

Products• CANCER IMMUNOMODULATOR——Better tumor penetration——Better cklearance (less side-effects)——Better flexibility for combinatorial therapies——Low cost of production

Area of Activity
Life sciences related activities

Foundation
3/10/2011

Company size
Employees
From 3 to 9 employees
TurnoverFrom 250.000 to 750.000 Euro

InfoHeadquarter——Stage of Development: Experimentation completed. Method validated.
• BREATHLESS——BreathLess, screening test of lung injury——Rapid and accurate detection of pattern of microRNA from all biologicalfluids——Assessment of lung damage in subjects exposed to environmental pollutants

Technology and Patents
1. A MiRNA sequence to be used in screening tests for lung injury with any
biological fluid.
2. A new peptide for anti-tumor treatments.
Patent Office and filing dates:
1. Italian Patent Office (UIBM) n.102017000034619 date 29 March2017, then
filed as PCT to WIPO, app.n. PCT/IB2018/052176, date 29 March 2018, pub. n.
WO/2018/178917 A1, with ISR and written opinion

Viale Europa, c/o Campus“S.Venuta”, Catanzaro
www.biotecnomed.It

2. Italian Patent Office (UIBM) n. 102018000003470, date 13 March 2018

Key Contact

Preferred Partner: Industry

Simona Lombardi
General Director

We are seeking for industrial partners interested in acquiring (licensing) andindustrializing our patented solutions

simona.lombardi@biotecnomed.it+39 0961 369 4279

2. Peptide: exclusive licensee $2M/5 years + 2-3% royalties

Giovanni Cuda
President
cuda@biotecnomed.it+39 0961 369 4225

Key opportunities

1. Breathless: exclusive licensee $1.5M/5 years + 2-3% royalties

Other opportunities
We have other projects available, already prototyped, patented and tested:• Wearable device (bracelet) for automatic analysis of tremor (discriminate PD
from benign tremor)• Wearable device (earclip) for automatic detection of sleep apnea and othersleep disorders
We are looking for industrial partners interested in acquiring the Intellectual
Property and in industrializing the solutions

20

Participating Company

CHIESI FARMACEUTICIDescription

Focus

Strategic partnerships

Based in Parma, Italy, Chiesi is an international research-focused Healthcare
Group, with over 80 years of experience in the pharmaceutical industry, present
in 26 countries. Chiesi researches, develops and markets innovative drugs in
the respiratory therapeutics, specialist medicine and rare disease areas. Its R&D
organisation is headquartered in Parma (Italy), and integrated with 5 other key
R&D groups in France, the USA, the UK, and Sweden to advance Chiesi’s preclinical, clinical and registration programmes. Chiesi employs more than 5,300
people.

Products
Most renowned products:

Area of Activity
Pharmaceutics

Foundation
9/3/1985

Company size
Employees
More than 499 employees
TurnoverMore than 50 million EuroInfo

• FOSTER - Foster is a fixed association of beclometasone dipropionate(corticosteroid) and formoterol fumarate (2 - long-acting agonist with a rapid
onset of action) to be taken by inhalation. In 2006, the drug was approved forasthma maintenance therapy.
• CLENIL - Active ingredient: Beclometasone Dipropionate• CUROSURF® (poractant alfa) - Intratracheal Suspension. It is indicated for the
rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants.
CUROSURF reduces mortality and pneumothoraces associated with RDS.

Technology and Patents
Chiesi’s products are chemical and biological drugs, most of which require
a medical prescription, and are mainly designed for primary care (General
Practitioners), particularly in the respiratory sector where the Group has several
leading products, and in special care, notably in neonatology, where the company
is a world market leader.

Headquarter

The Group has developed the technological platforms Modulite® (a pressurised
metered-dose inhaler) and NEXThaler ® (dry powder inhaler) for theadministration of respiratory drugs.

Via Palermo 26/A, Parma
www.chiesi.com

Patent Office and filing dates :Key Contact

Ugo Di Francesco
CEOu.difrancesco@chiesi.com+39 05 212 793 73

More than 3000 entries – details upon request.

Key opportunities
Preferred Partner: Industry & R&D

Other opportunities
BD activities

21

DOMPÉ FARMACEUTICIDescription
Dompé is an Italian bio-pharmaceutical company focused on innovation in the fieldof personal wellness and R&D. Headquartered in Milan, the industrial and biotech
hub, and R&D division are in L’Aquila and Naples (Italy); other branches in the USA
and in Europe.

Focus

Strategic partnerships

Dompé is focused on development and distribution of ethical and OTC drugs totreat pain, inflammation, and respiratory disorders, as well as rare diseases andorphan drugs. This goal is pursued through R&D programs on high unmet medical
needs using a network of over 200 excellence R&D centers. In ophthalmology,
Dompé recently launched the first drug based on rhNGF for the treatment ofpatients suffering from a rare ocular disease.

Products

Area of Activity
Pharmaceutics

Foundation
11/14/1940

Company size
Employees
More than 499 employees
TurnoverMore than 50 million Euro

InfoHeadquarter

Via San Martino 12, Milano
www.dompe.com
Key Contact

Eriona Gjinukaj
Chief Operating Officereriona.gjinukaj@dompe.com+39 02 58383560

Marcello Allegretti
Chief Scientific Officer
marcello.allegretti@dompe.com+39 0862 338212-216

Dompé, with its products offered at over 10,000 pharmacies in Italy, is engaged in
the development and distribution of ethical drugs and self-medication, adjuvants,
medical devices and cosmetics, and in the fields of vitamin and mineral supplements
and personal hygiene. The therapeutic areas include cardiovascular, gastrointestinal,
paediatrics, neurology, urology, ophthalmic, stomatology and respiratory.
In 2016 Dompé acquired the pharmaceutical division of Bracco, an Italian company,
thus further expanding its own product list. Dompé Primary Care operates throughtwo distinct lines: ethical drugs and self-medication.
The close synergy between the two lines allows for an efficient and coordinatedsupply of information about products to doctors and pharmacists alike, and an
efficient distribution system that can satisfy all the needs of any given local area,from those of the hospital distribution channel to the pharmacy one.
Dompé currently markets 50 million medication packages in roughly 40 countries
around the world.

Technology and Patents
The Biotech unit is a manifestation of Dompé commitment to meeting unsatisfied
patient needs all around the world.
The company pursues this ambitious goal through its commitment to Researchand Development in fields characterised by high therapeutic needs, using an “openinnovation” logic that finds Dompé collaborating with 200 international research
centres of excellence in the search for therapeutic solutions to health needs thathave yet to be resolved.
The Biotech Unit focuses specifically on the rare diseases field, such as ophthalmology,
for instance, an area in which the company has developed and marketed the firstophthalmic product based on rhNGF (the molecule discovered by Nobel Prize winner
Rita Levi Montalcini) for patients suffering from neurotrophic keratitis.
In accordance with its vocation, Dompé has major partners in the therapeutic
innovation field, particularly in biotechnology.
A major shareholder in Philogen, a Swiss-Italian biotech company that specialises
in bio-pharmaceutical products for the treatment of cancer, rheumatoid arthritis
and some ophthalmic diseases. In 2012 Dompé became the majority shareholderof AAA - Advanced Accelerator Applications - a leader in the field of molecular
medicine that focuses on Research & Development and the production of radiopharmaceuticals for molecular imaging and personalised medicine.

Key opportunities
Preferred Partner: Distribution/Trade
Licensing opportunities in markets out of EU (Italy, France, Spain and Germany),
USA and Canada for Oxervate.

Other opportunities
22

Partnering for licensing in and out in the field of rare diseases (late preclinical andclinical stage).

Participating Company

DOPPEL FARMACEUTICIDescription
Doppel is today recognized as one of Europe’s leading experts in contract
R&D and manufacturing. It has start-of-the-art facilities and highest scientificcapabilities to service its international pharmaceutical and nutritional clients.

Focus

Strategic partnerships

The company is committed to applying its innovative technologies, deep
knowledge and broad experience to develop products of the highest quality for
its customers worldwide.
In particular, Doppel provides a specialist consultative service to customers prior
to each project in order to determine together the most effective and bespoke
solution for the product.

Products• Liquids Large Volume (Glass + PE)

Area of Activity
CMO——Solutions——Suspensions——Syrups

Foundation
1/1/1994

Company size——Mouthwash——Vaginal solutions——Liquids Small Volume——Drops

Employees
More than 499 employees——Drinkable vials

TurnoverMore than 50 million Euro——Creams, Gel, Ointment

Info
Headquarter

Via Martiri delle Foibe 1,
Cortemaggiore (PC)www.doppel.itKey Contact

Marco Conte
Board Member
mconte@trilanticeurope.com+39 340 535 36 43

Giorgio OberrauchCEOg.oberrauch@doppel.it——Throat sprays——Suppositories and Ovules——Soft Gelatine Capsules——Highly Potent Drugs (tablets)——Food Products——Ampoules (SFI)——Aseptic filling——Final sterilisation• Solid Oral Dosage Forms (blisters)• Plain tablets——Coated tablets——Vaginal tablets——Hard gelatine capsules• Sachets• Liquids Large Volume• Liquids Small Volume (drops)

Technology and Patents
Doppel manufactures Oral Solids, Creams, Gel, Ointment Suppositories andOvules, Soft Gelatine Capsules, Ampoules, Vials, Sachets.

Key opportunities
Preferred Partner: Industry

Other opportunities
Networking

23

EPYGON ITALIE
Description
Biomedical company developing a trans-catheter biological mitral valve
prosthesis and its delivery systems.

Focus

Strategic partnerships

Products
EPYGON, the innovative transcatheter mitral bio-prosthesis
Epygon valve is conceived to match the hemodynamic and anatomic features of
the native mitral valve.
Indeed, Epygon valve is the first “physiological” transcatheter mitral prosthesis
because it can restore the natural blood flow vortex in the left ventricle, thereby
fostering recovery of ventricular functions, especially in fragile patients with aseriously impaired cardiac condition.

Area of Activity
Medical devices

The key features of Epygon valve are:• D-shape annular ring
• Monoleaflet• Asymmetric stentFoundation
3/25/2015

Company size
Employees
From 10 to 19 employees
TurnoverFrom 75.000 to 250.000 EuroInfo

• Anatomic atraumatic anchoring system
The conceptual design of our transcatheter mitral bioprosthesis allows a uniquegeometry for an optimal fitting to mitral anatomy and an advanced monoleaflet
structure for a physiologic hemodynamics and low risk of LVOT obstruction. The
Epygon prosthesis is delivered to the implant site via antegrade (transatrial/
transeptal) or retrograde (transapical) “off-pump” transcatheter access.

Technology and Patents
Patents related to the design (metal and biological components) of the bioprosthesis and its related delivery systems.

HeadquarterKey opportunities

Via Ribes 5, Colleretto Giacosa(TO)
www.epygon.com

Preferred Partner: R&DKey Contact

Partners interested in financing the R&D activity until the CE mark of the product.

Stefano Pasquino
Amministratore Unicostefano.pasquino@epygon.com+39 0125 1906906

Enrico Pasquino
CTO - Chief Technical Officer
enrico.pasquino@epygon.com

24

Other opportunities

FLAMMA GROUP
Description

Focus

Strategic partnerships

A privately held company with over 60 years of experience, Flamma Group
has a solid reputation for continuous delivery of high quality pharmaceuticalintermediates and APIs to the pharmaceutical market. From gram to tons, from
R&D to Regulatory filing, Flamma manufacturing expertise and state of the art
quality system helps small and large pharma company to successfully develop a
reliable process, transfer, and scale-up APIs and intermediates.
Flamma has two FDA and AIFA approved cGMP manufacturing facilities locatedin Italy and a cGMP manufacturing facility located in China, 3 R&D centers, andoffices in Boston and Paris.

Products

Area of Activity
Chemical & APIs

Foundation
4/1/1950

Company size

Flamma produces a wide-ranging list of generic APIs, including products like
Melatonin, Minoxidil, Sulindac, and many more. Our Active Ingredients include
compounds like Asparagine. Our Intermediates consist of numerous high-valueamino acid derivatives including Moc-Valine and Cbz-L-Alanine.
• Acetyl-DL-Leucine• L-Arginine-L-Aspartate• Di-Ornithine Ketoglutarate L-Ornithine-a-Ketoglutarate L-Ornithine2-oxoglutarate• Hydrochlorothiazide

Employees
More than 499 employees• Ketoprofen Lysine Salt

TurnoverMore than 50 million Euro• Melatonin (MelaPureTM)

Info
Headquarter

Via Bedeschi 22, Chignolod’Isola (BG)
www.Flammagroup.com
Key Contact

Gianmarco Negrisoli
Corporate Development
Managergm.negrisoli@flammagroup.com+39 339 789 26 64• Magnesium-DL-Aspartate• Methacholine chloride• Minoxidil• Modafinil• Nimesulide micronized• L-Ornithine-L-Aspartate• DL-Phosphoserine• L-Phosphoserine• L-Phosphothreonine• Potassium-DL-Aspartate

Technology and Patents
Flamma is a Technology company with an R&D group of more than 85 scientists
dedicated to the discovery and optimization of competitive and sustainable
syntheses for the manufacturing of innovative as well as off-patent drugs.

Giampaolo Negrisoli
CEO
mngdir@flamma.it+39 335 696 70 50

Key opportunities
Preferred Partner: Industry
Flamma is actively looking to expand its US footprint both on the R&D side
and commercial side, as well as through partnership for the development ofinnovative technologies in the field of synthetic chemistry.

Other opportunities
Opportunities in the high end nutraceutical or cosmeceutical market.

25

Participating Company

IQVIA SOLUTIONS ITALY
Description
Quintiles and IMS are now IQVIA.

Focus

Strategic partnerships

IQVA is committed to providing solutions that enable healthcare companies
to innovate with confidence, maximize opportunities and, ultimately, drive
healthcare forward. This happens via breakthroughs in insights, technology,
analytics and human intelligence that bring the advances in data science
together with the possibilities of human science.

Products
Solutions and Services:• Asset Valuation & Due Diligence• Drug Development Strategy & Analytics

Area of Activity
Life sciences related activities

Foundation
11/6/2017• Clinical Development• Launch Strategy & Planning• Commercialization & Lifecycle Management

Key opportunities
Preferred Partner: Industry

Company size

Looking for new contacts with biotech companies, start-ups, willing to enter the
Italian market.

Employees
More than 499 employees

Offering full support from molecule to market: asset evaluation, clinical andregulatory support.

TurnoverMore than 50 million Euro

InfoHeadquarter

A.Holding, Inc - Headquarters
Durham - 4820 Emperor Blvd
- North Carolina USA
www.iqvia.com
Key Contact

Sergio Liberatore
Sr.Vice President & General
Manager,Italy & Greece
sergio.liberatore@iqvia.com+39 02 69786 330

Daniela Sica
Associate Director, Emerging
Biopharma, Italy
daniela.sica@iqvia.com
02.69786330

26

Other opportunities
New contacts with venture capitals in order to create a partnership to enhance
the start-ups development.

Participating Company

ITEM OXYGEN
Description

Focus

Strategic partnerships

The Item Oxygen S.r.l. is an Italian company operating in the medical field for overtwenty years. Its main activity is the design, installation, service and maintenanceof plants for the distribution of medical gases. This activity adds to the design
and manufacture of medical devices intended for assistance in monitoring somebasic parameters for the assistance and care of patients, both in the home,with particular reference home care and sub areas, including through the use ofpredictive systems.

Products

Area of Activity
Medical facilities furnishings,
equipment, goods

Foundation
11/7/2003

Company size
Employees
From 20 to 49 employees
TurnoverFrom 2.5 to 5 million Euro

InfoHeadquarter

Via Le Fogge 11, Altamura(BA)
www.itemoxygen.com
Key Contact

Giovanni Piccininno
Scientific Director of Item
Oxygen Research Instituteg.piccininno@itemoxygen.com

Merystella Magrino
R&D Amministration Manager
m.magrino@itemoxygen.com• H@H hospital at home - Web based system of real-time telemonitoring andtherapy for patients at home of the itemoxygen.
In addition to monitoring all the physiological parameters of the patient, italso allows the administration of oxygen therapy by means of an oxygen
concentrator and endocavitary aspiration.
The H@H hospital at home system has been awarded for its highly innovative
component. The device won the ADI DESIGN INDEX 2013 and was exhibited at
the TRIENNALE DI MILANO.
• H@H smartmews - H@H Smartmews is one of the most advanced devices
used for the monitoring of vital parameters and for automatic calculationof graveness scores (MEWS; PESI, Shock Index, Sepsi Screening Tool). The
automatic evaluation of such scores allows health personnel to recognize thepatient’s clinical condition early. The system also allows the automatic andinteractive implementation of important clinical protocols.
• H@H-Care - It is an innovative all-in-one home medical system. H@H e-Careallows simultaneous and remote activation of video consultation and displayof the patient’s clinical parameters, resulting in a clinical instrument “close to
the patient”. Users are able to manage and get a history of all the clinical datadetected, such as: blood pressure, blood glucose, SpO2, body temperature,etc. At any time of the day and at any place, the doctor can know the values ofclinical parameters through an internet connection.

Technology and Patents
Title: “Apparatus and system for preventing and extinguishing fires, installable on
heavy goods industrial vehicles”.
Patent Office and filing dates:
EP 3 269 427 A1 - 14/07/2016

Key opportunities
Preferred Partner: Distribution/trade, R&D, Industry
Item Oxygen S.R.L. combines innovation, technological culture, training andmedical-scientific research. The company, to develop and devise the most avantgarde solutions in medical ambling, is constantly looking for qualified partners
with whom to collaborate.

27

Participating Company

KEDRION
Description

Focus

Strategic partnerships

Kedrion Biopharma is an international company that produces and distributes
plasma-derived medicinal specialties for use in treating and preventing serious
diseases, disorders and conditions such as Hemophilia, primary immune system
deficiencies and Rh sensitization, which can lead to hemolytic disease of the
fetus and newborn.
The company acts as a bridge between donors and the people who needtreatments, and works on a global scale to expand the patients’ access toavailable treatments
In Italy, Kedrion is a partner of the National Health System, which it concretely
supports in the pursuit of self-sufficiency in the supply of plasma-derived
products.

Area of Activity
Pharmaceutics

Foundation
1/6/2000

Company size
Employees
More than 499 employees
TurnoverMore than 50 million Euro

InfoHeadquarter

Loc. ai Conti Snc,
Castelvecchio Pascoli (LU)
www.kedrion.com
Key Contact

Federico Moro
Public Affairs Manager
f.moro@kedrion.com+39 335 688 10 77

28

Products
Product portfolio covering multiples areas• Hematology/hemophilia• Immunology/neurology• Critical care
• Medical devices• Products dedicated to the national self-sufficiency program in italy

Key opportunities
Preferred Partner: Distribution/Trade
The company is mainly involved in the United States Market in the so called
Hemolytic Disease of tbe Newborn, a rare condition affecting women Rh-. Whilethe disease is eradicated in US and in main Western countries, it is still a problem
Worldwide, Kedrion is looking for partners to develop a common global strategy,
in particular Institutions, Industries, NGOs, Grantamakers.

Participating Company

LABORATORIO FARMACEUTICO C.T.
Description

Focus

Strategic partnerships

Manufacture of medicinal products and contract manufacturing activities.
Commercialization of proprietary medicinal products. Research activities in thefield of addiction. High specialization and expertise in the treatment of Alcohol
Use Disorders (AUD). Pioneer in the field of pharmaceutical treatment of alcohol
addiction, LABCT offers a unique opportunity to invest in a new molecular entity
and second generation compounds.

Products
Laboratorio Farmaceutico CT Srl has become a flexible and reliable partner inyour pharma supply chain for:• Injectable antibiotics Cephalosporins• Injectable antibiotics Penicillins

Area of Activity
Pharmaceutics

Foundation
11/14/1946

Company size

• Antibiotics ampoules• Non antibiotics tablets, capsules, suspensions and syrups• Products composed by controlled substances

Technology and Patents
Patents on New Molecular Entities (NMEs) and their pharmacological use.
Patents on manufacturing procedure of NMEs.

Employees

Patents on new polimorphic forms of selected chemical compounds.

From 100 to 499 employees

Patent Office and filing dates:

Turnover• EPO - August 8, 1997

From 15 to 50 million Euro• US - August 8, 1997

Info
Headquarter

Via Dante Alighieri 71,
Sanremowww.labct.it
Key Contact

Roberto Cacciaglia
Chief Scientific Officer• US - November 13, 2008
• AU - November 13, 2008
• JP and China - November 13, 2008
• EA (Eurasian Pat. Conv.) - November 13, 2008
• EPO - October 29, 2015
• US - June 3, 2016
• CDN – June 3, 2016
• IT - June 1, 2016
• PCT - August 3, 2016

roberto.cacciaglia@labct.it+39 01 845 92 41

Key opportunities

Giuseppe Tessitore
Chief Executive Officer

LABCT aims at bringing a new chemical entity for treatment of AUD to a phase
II clinical stage development, looking then for an out-licensing and/or a potential
exit for shareholders that can materialize in an M&A transaction or IPO. LABCT
will aim at bring the lead compound at a phase II stage expected at end of 2021
looking then for an exit strategy and or out-licensing event.

tessitore@labct.it+39 01 845 92 41

Preferred Partner: Industry

Other opportunities
A new vehicle (NewCo) can be also created including the patent portfolio
related to the NME and R&D technology platform and will leverage on the overall
expertise and know-how of LABCT team on alcohol abuse treatments and on ahighly qualified international advisory board.

29

MEDIOLANUM FARMACEUTICIDescription
Pharma Company, with products for speciality and primary care, now oriented tointernational development through partnerships in oncology.

Focus

Strategic partnerships

Products
Mediolanum has granted licences for the following products resulting from its
research activities:• Mesoglycan• Rufloxacin• Iron acetyltransferrin• Dermatan sulphate

Area of Activity
Pharmaceutics

Foundation
1/1/1972

Company size
Employees
More than 499 employees
TurnoverMore than 50 million Euro

InfoHeadquarter

Via S.Giuseppe Cottolengo 15,
Milanowww.mediolanum-farma.com
Key Contact

Millet Bernard
International Director
b.millet@mediolanum-farma.com

30

These products are sold or have been granted marketing authorization in Italy
and other European countries, South America, the Far East and Africa.

Technology and Patents
The Mediolanum group has always considered the research and development oforiginal and innovative products and/or methods an integral and fundamental
part of its business and dedicated a large part of its efforts to these activities.
The results obtained confirm and reward this commitment: 93 new inventions
or discoveries have resulted in over 700 patents being filed in more than 40
countries.
Mediolanum completed the development of no fewer than 4 products between
1980 and 1999: Mesoglycan, Iron acetyltransferrin, Rufloxacin and Dermatansulphate.
An innovative, original subcutaneous controlled-release system for administeringvarious types of medicinal products, structured on ten technological platforms(MeDeSys).

Key opportunities
Preferred Partner: R&D

Other opportunities
US Biotech companies.

PANOXYVIRDescription
Panoxyvir opens a new frontier in antiviral research by turning physiologicalcholesterol metabolites into drugs to fight a broad range of viral infections.

Focus

Strategic partnerships

Panoxyvir aims to adopt an innovative approach to antiviral prevention and/or
treatment that is targeting the site of infection by a given pathogenic virus rather
than the viral particles themselves. Research and development are focused on
the wide and remarkable antiviral effects displayed in vitro and ex vivo models bydefined cholesterol oxidation products (oxysterols) of physiological origin.

Products

Area of Activity
Pharmaceutics

Foundation
11/7/2016

Company size

• Anti-Rhinovirus Nasal Spray - Stage of Development: Preliminary organic
synthesis and formulation of the active substance. Its validation in 3D
reconstituted human nasal and bronchial epithelia. Pharmacokinetics studies inprogress.
The inhalation of the active ingredient will be suitably afforded by a medical
device allowing to reach the whole nasal mucosa and to reduce to a minimum
if any the involvement of the lower respiratory tract.

Technology and Patents
Use claims: protection of a class of oxysterols against
RHINOVIRUS and associated pathologies

Employees

PAPILLOMAVIRUS and associated pathologies

Less than 3 employees

ROTAVIRUS and associated pathologies

TurnoverFrom 75.000 to 250.000 Euro

Italian patent: granted 3/10/2016

InfoHeadquarter

Corso Vinzaglio 16 c/o Studio
Jona, Torino
www.panoxyvir.com
Key Contact

David Lembo
CEOand CSO
david.lembo@panoxyvir.com+39 3457183549

Giuseppe Poli
President and CEO
giuseppe.poli@panoxyvir.com+39 3405732509

PCT application: n. IB2015/055000 (July 2, 2015)
PCT national phase extension: Europe, USA, Canada, Australia, Japan

Key opportunities
Preferred Partner: Industry
A pharmaceutical firm could most likely help Panoxyvir in successfully achieving
the non clinical steps still to be obtained up to the entry into human. They could
validate or better focus the company’s actual positioning and, above all, they
could suitably and successfully direct the business development.
Prevention and/or treatment of severe and not rarely lethal exacerbations
rhinovirus-induced of chronic respiratory diseases, like cystic fibrosis (CF)and asthma. Actual estimated global market values for CF and asthma arerespectively €3.13BLN and €18.2BLN.

Other Opportunities
Once properly directed, the development of Panoxyvir’s business project wouldmuch benefit from the involvement of financial investors as well.

31

Participating Company

PETRONE GROUP
Description

Focus

Strategic partnerships

PETRONE GROUP is a wholly privately-owned family company active worldwide
in the pharmaceutical, para-pharmaceutical and health Sector. Experts in logistics
and distribution of medicinal products including “restricted” drugs and cold
chain products. PETRONE GROUP expertise covers all the drug product lifecycle:
from clinical trials, to early access and logistics. Petrone Group acts as a valuablebridge for clinical sponsors, CROs, Pharma and biotech companies willing toreach physicians, hospitals and patients at very critical stages.

Products
European Hub Services available at any of our locations in Italy, Spain and Ireland:• Company set up• Fiscal support

Area of Activity
Life sciences related activities

Foundation
11/8/1989

Company size

• Financial and Accountancy• Legal service• Customs Clearance• Regulatory Support• Pharmacovigilance• Tendering Activity• Market Access

Employees• Business Development

More than 499 employees• Logistic

TurnoverMore than 50 million Euro• Commercial Services

InfoHeadquarter

Via Artemisia Gentileschi 26,
Napoliwww.petrone.it
Key Contact

Pierluigi Petrone
CEOpierluigi@petrone.it+39 335 493 932

32

Key opportunities
Preferred Partner: Distribution/Trade

Other opportunities
CRO medical device.

Participating Company

RECORDATI
Description

Focus

Recordati is an international pharmaceutical group dedicated to the research,development, manufacturing and marketing of pharmaceuticals for primaryand specialty care as well as orphan drugs for the treatment of rare diseases.
Headquartered in Milan, Italy, Recordati has operations throughout the wholeof Europe, including Russia, Turkey, North Africa, the United States of America,
Canada, Mexico, some South American countries, Japan and Australia. Recordati
has been listed on the Italian Stock Exchange since 1984.

Products
Core Products:

Area of Activity
Pharmaceutics

Foundation
5/1/1926

Company size
Employees
More than 499 employees
TurnoverMore than 50 million Euro

InfoHeadquarter

Via Civitali 1, Milano
www.recordati.it
Key Contact

Luigi Longinotti
Head Portfolio Management Orphan Drugs
longinotti.l@recordati.it+39 344 01 62 577

Pierpaolo Ferlenga
Corporate Licensing Manager
ferlenga.p@recordati.com• Zanidip® (lercanidipine) - Lercanidipine is a proprietary latest generation
calcium channel blocker indicated for the treatment of hypertension. Sales ofZanidip® are expected to remain stable at between € 110 and 120 million going
forward.
• Zanipress® (lercanidipine + enalapril) - Enalapril is an ACE inhibitor indicatedfor the treatment of hypertension.
• Urorec® (silodosin) - Highly selective alfa1A receptor antagonist indicatedfor the treatment of symptoms associated with benign prostatic hyperplasia(BPH). BPH market in 15 main countries approx. € 0.9 billion.Urorec® sales in2019 expected to exceed € 100 million.
• Livazo® (pitavastatin) - Highly effective HMG-CoA reductase inhibitor indicatedfor the treatment of hypercholesterolaemia and also a potent LDL-lowering
drug with a consistent and progressive HDL-raising effect (Atherosclerosis
Supplements 2010; 11:15-22).
Expect sales to continue to grow double digit through 2019. Statins market in
the 6 main countries is of around € 0.9 billion.
• Seloken®/Seloken® ZOK (metoprolol succinate) - Metoprolol succinate is abeta-blocker mainly indicated for the control of a range of conditions includingof hypertension, angina pectoris, disturbances of cardiac rhythm, maintenancetreatment after myocardial infarction, and functional heart disorders with
palpitations.
• Logimax® (metoprolol succinate+ felodipine) - Logimax® is a fixed combinationof metoprolol succinate and felodipine, a calcium channel blocker indicated forthe treatment of hypertension.

Key opportunities
Preferred Partner: Industry
Recordati looks for licensing or acquisition opportunities for their territories(globally only for Rare Diseases) to strengthen its corporate portfolio.
Opportunities should fall into the following areas:• Urology• Cardiovascular• Gastrointestinal• Metabolic Diseases• Orphan and Rare Diseases• Self-medication• Central Nervous System• Preferred opportunities in late stage of development.

Other opportunities
Selected R&D opportunities at early development stage can be of interest at
certain conditions.

33

Participating Company

SOFAR
Description
SOFAR S.p.A., Italian pharmaceutical company, based in Milano area, establishedin 1968 and up to date 100% Italian private capital company. SOFAR’s core value
and objective is to bring to the market unique, clinically proven products.

Focus

Strategic partnerships

SOFAR owns and markets high quality pharmaceuticals, dietary supplements
and medical devices, dedicated to gastroenterology, urology, dermatology,
gynecology and general healthcare. Whilst Company’s main market is Italy, it isexponentially expanding into other markets, exporting its products, both throughits subsidiaries (USA, Switzerland, Russia, Romania, Lithuania) as well as throughpartnerships in Europe, MENA, Asia, Australia.

Products

Area of Activity
Pharmaceutics

Foundation
12/12/1968

Company size
Employees
From 100 to 499 employees
TurnoverMore than 50 million Euro

InfoHeadquarter

Via Firenze 40, Trezzano Rosa
(MI)
www.sofarfarm.it• Pentacol® - Mesalazine, the leading product in Italian market and in SOFAR
gastroenterology products line. Recently launched PENTACOL 1200 mg gastroresistant modified-release tablets.
• Enterolactis® - Probiotic product line based on SOFAR proprietary LP-DG™
strain, number one dietary supplement in Italy.
• Gerdoff® - innovative patented medical device for treatment ofgastroesophageal reflux disease.
• Cistiflux® - Dietary supplement as aid in UTI treatment, market leader in its
segment.
• Innovia™ - Innovative probiotic product recently successfully launched in USA
and approaching other worldwide markets.
• Sofargen® - A product line for topical use based on Silver-Sulfadiazine. The
World Health Organization has included it in the list of the 200 essential
medicines.
• Senhance™ - The first and only digital laparoscopy surgical system, CE marked
and FDA approved. Digitizes the interface between the surgeon and patient inlaparoscopy to increase control and reduce surgical variability in today’s valuebased healthcare environment. The SenhanceTM Surgical System removes the
economic limitations of current robotic systems with fully reusable instruments
and an open-platform architecture strategy that enables hospitals to leverage
existing technology investments.

Key Contact

Key opportunities

Andrea Biffi
CEO

Preferred Partner: Industry

andrea.biffi@sofarfarm.it

Egle Gedrimaite
Business Development
Director Foreign Markets
egle.gedrimaite@sofarfarm.it

34

R&D, Distribution, License

LIFE SCIENCES
CLUSTERSREGIONE PUGLIA

ApuliaInfrastructures andconnections
 2 international airports (Bariand Brindisi), serving over 40
international destinations
 1 industrial cargo airport(Taranto-Grottaglie), recently
adopted as a test-bed forremotely piloted aircraft
and designated as the firstspaceport in Italy for thedevelopment of sub-orbital
flights
 3 major ports: Taranto(container shipping; the 3rdlargest commercial port in
Italy for cargo traffic); Bari
(passenger and container

traffic); Brindisi (passenger
traffic)
 Extensive road and railway
networks, linking the region to
major north-south corridors
and high-speed rail network 1 logistics Interport located in Bari

FACTS &FIGURES

Industrial base226 companies active in Life
Sciences (including Sanofi
and Merck), with over 1,650
employees.

Apulia plays a leading role in thepharmaceutical sector in Italy
and is one of the main regions forexports, thanks to the presenceof multinational companies,
including Sanofi e Merck whichhave located manufacturing
plants and research facilities in
the region.
The region has also gained
recognition as a center of
excellence for precision medicine,with the recent creation of
the national Hub for precision
medicine, TecnoMED, which
carries out innovative research fortumors and neurodegenerative
diseases, based on
nanotechnologies.

Contact info
PUGLIA SVILUPPO
www.pugliasviluppo.eu
fdi@pugliasviluppo.eu+39 080.5498811
Theresa Mulloy
Ewa Jankowska

38

medicine; Advanced Therapy;
Molecular and advanced
diagnostics; New manufacturing
processes.

Synergy between private andpublic research institutes aims
at advancing research andencouraging the creation of local
technological businesses that
can industrialize research results
and bring patents to markets
in areas such as biotechnology
drugs, gene therapy, somatic
cell therapy, tissue engineering,biomarkers, drug discovery
and drug delivery, advanced
diagnostics, bioinformatics.
H-BIO - Apulian Biotech Cluster(11 public and 25 private partners)
is a key player in this area andbrings together the interests
and activities of both regional
universities and research centersand private companies operatingin the fields of healthcare andbiotech-drugs, focusing on 4
strategic sectors: Personalized

The regional export ofpharmaceuticals and chemicals
in 2017 amounted to over 1.6
billion Euros.
Main business sector
specializations: Advanced Pharmaceuticals
 Biomedical Devices
 Advanced Diagnostics
 ICT (Bioinformatics –Telemedicine- eHealth) Cosmetics
 Surgical and Medical
Supplies

R&D network

Success story

3 major Universities (Bari, Foggia, Salento) and 1
Polytechnic University (Bari) In 2018, Gelesis, a biotechnology company
based in Apulia and co-founded by
PureTech Health (an advanced, clinicalstage biopharmaceutical company from
Boston - USA), developing first-in-classmechanotherapeutics to treat chronic diseases
related to the gastrointestinal (GI) pathway,
closed an international financing round,raising $ 30 million of funding. The proceedsfrom the financing will be used to support
commercial-stage manufacturing, productlaunch preparations, company operations,and clinical advancement of the Company’s
pipeline of additional product candidates for
gastrointestinal disorders, including Type 2
diabetes and non-alcoholic steatohepatitis/
non-alcoholic fatty liver disease (NASH/
NAFLD). The Company has also submitted
Gelesis100 for regulatory approvals in the US
and Europe in 2018.

3 specialised Hospital Research Institutes
 IRCCS Istituto Tumori “Giovanni Paolo II”(specialised in cancer research) IRCCS “Casa Sollievo della Sofferenza”(specialised in genetic diseases)
 IRCCS “Saverio de Bellis” (specialised inmolecular biology and degenerative diseases)
2 National Research Centres
 National Research Council (CNR), present inApulia with 6 research institutes, including
NANOTEC – Institute of Nanotechnoloy whichhosts TecnoMED
 National Institute for Nuclear Physics (INFN)
CVBF - Biological and Pharmacological Evaluation
consortium for research and product testing
C.A.R.S.O. Consortium for post-doc training
in biomolecular and oncological research andtreatment

Incentives and funding
Regional Contract Programmes: regional grants
scheme supporting business innovation andinvestment projects for existing companies or for
new companies to be located in the region, withinvestment budgets falling within the range between
5 million and 100 million Euros.
Integrated Incentives Packages (PIA): regional
grants scheme supporting business innovation andinvestment projects for existing SMEs or new ones
to be set-up in the region, with investment budgets
falling within the range between 1 million and 40
million Euros.
Tecnonidi: regional grants initiative which supports
investments projects for innovative start-ups andSMEs, with a high-technology content aimed at
introducing new products, services and/or businesssolutions, with investment budgets falling within therange between 25,000 and 350,000 Euros.

Sites and buildings
2 Business Incubators located in Puglia Sviluppo’s
premises in Modugno (BA), suitable for service
industry and digital start-ups and Casarano (LE),suitable for research and manufacturing activities.
H BIO - Apulian Biotech Cluster based in the
University of Bari.

 In 2017 the French multinational Sanofi, active inpharmaceutical sector decided to invest 6 million
euros in the Brindisi plant, for the developmentof an industrial biotechnology project thataims to develop innovative technologies for the
genetic improvement of the microorganisms andof the processes of fermentation extraction andpurification of active ingredients.

Business opportunity
CAREPY DIGITAL START-UP
Equity Investment
Value of investment: between 600,000 and
2,500,000 Euros.
Carepy is a digital start-up which developed
and launched an App that simplifies therapy
management by connecting pharmacists, treating
physicians, patients and family members.
Carepy provides patients with a digital healthassistant through a mobile app that: alerts users about taking medication, taking
measures, keeping an appointment or goingback to a pharmacy
 establishes a direct channel of communication
for patients, their pharmacy and doctor,
proactively supporting therapeutic adherence
and monitoring the levels of individual drug
consumption
 allows the pharmacist to manage targeted
promotion and activities on individuals orgroups of patients
 ensures specialist doctors follow the treatment
cycle in real time and improve the complianceof patients during de-hospitalization
Corporate and equity investment: the company
is looking for financial partners to financethe development of new chronicity anddehospitalization management platforms tointegrate with the current software solution andramp-up sales and marketing.
39

Friuli Venezia Giulia
Infrastructures andconnections
 Airports: Venice Marco Polo
Airport, Treviso A. Canova
Airport and Trieste Airport
Friuli Venezia Giulia are 30/60
minutes driving from regional
main towns
 Main Highways: E70-A4 TurinMilan-Trieste, A23 PalmanovaTarvisio, A28 PortogruaroConegliano Railway: Connections from
Udine and Trieste railway
stations to Milan, Rome, Turinand Venice Maritime connections: Trieste,
Monfalcone and Porto Nogaro
commercial ports

 Interports: Cervignano,
Pordenone and Trieste
 Broadband: ERMES, with its
2,600 km of cables, 260,000
km of optical fiber, 1,679 km of
backbone infrastructure and
720 km of cable infrastructurein the 86 industrial areas,is the wider broadband
geographic area in Italy

Industrial baseBio-high-tech in Friuli Venezia
Giulia consists of about 150
companies working in Smart
Health within three closely related
Bio fields: Bio-Med (including
Living Environment Technologies),
Bio-Tech and Bio-ICT.
Among the big companies,
we can mention TBS Group(biomedical hospital devices
corporation), Lima Corporate(one of the world leading
companies in prosthetics),
and Biofarma (working in
nutraceutical). Average
enterprises include ALIFAX andInsiel Mercato, while small andmicro enterprises represent 90%of the whole field.

Contact info
Central Directorate for
productive activities andtourism
www.regione.fvg.it/rafvg/cms/
RAFVG/ economia-impresewww.investinfvg.it
investinfvg@regione.fvg.it
040/3772448 - 040/3772423
Antonio Bravo (Central Director)
Rodolfo Martina
Michela Masoch40

FACTS &FIGURESSMART HEALTH CLUSTER
Export: 300-315 mln €Turnover: 900 mln €Enterprises: 150
Employees: 5,000
Foreign companies: 27
BIOHIGHTECH INDUSTRY
FOCUS
 Biomedical
 In vivo and in vitro
diagnostics
 Medical informatics andBioinformatics
 Innovative Therapy
 Ambient Assisted Living

R&D network

Incentives and funding

Key players in research and innovation: 150
companies (Bio-med and in-vivo diagnostics 30%,
in vitro diagnostics 18%, Medical informatics 20%,
Innovative therapies 17%, Ambient assisted living
15%; 3 Universities (Trieste, Udine, Sissa); 2 CNR
sites; 5 international research institutes (ICGEBInternational Centre for Genetic Engineeringand Biotechnology, Elettra Sincrotrone, LNCIB(Biotechnologies University Consortium National
Laboratory); Fondazione Italiana Fegato (ItalianFoundation for Liver); Callerio Foundation(oncologic diseases); Area Science Park; 2 IRCCS- Sanitary research and care Institutes (Burlo
Garofolo in Trieste and CRO in Aviano, Pordenone);
2 academic medical center hospitals (Trieste andUdine, both certified by the Joint Commission
International); 4 technology and science hubs. The
Burlo Garofolo Pediatric Institute is a children’s
hospital recognised as the best one in Italy for its
research activity and 28th all over the world.

Friuli Venezia Giulia Region has several types fo
incentives and funding: Regional taxes reduction
can be applied to companies which meet specificcriteria; public grants can be awarded to support
the creation of new enterprises and implement
RDI projects. There are also incentives to support
competitiveness of SMEs and measures to financeinnovation technology investments. Different kindsof regional subsidised loans can be granted tosupport investments and business development.

Know-how and specialisation in the following
fields: in vivo diagnostics, prosthetics, regenerative
medicine, biosensors and advanced microscopy,
in vitro diagnostics and bio-pharmaceutics (biosimilar) with particular specialisation in cardiology,
neurology, oncology, pediatrics, gynecology,
genomics (Next Generation Sequency), nutraceutics,
informatics, including all the IoT (Internet ofThings) technologies (telecommunications, bigdata, informatics safety, cloud infrastructures forhealth, mobile technologies), all the HPC (High
Performance Computing) technologies, hospital andwelfare information technology, bio-images and biosignals IT, telemedicine, remote assistance, smart
home automation systems, wearable technologies,
decision support systems.
CBM is the cluster organisation of the Smart Health
Cluster of Friuli Venezia Giulia with a leading rolein building relationships between all the actors inthis field - entrepreneurs, researchers, clinicians,
policy makers and people involved in finance andeducation.
CBM is focused on internationalisation activity inorder to increase its network with European countries(i.e. Bavaria, Austria, Poland, Balkan regions) and U.S.,
Cuba, Thailand, Australia and others.

Sites and buildings
Area Science Park – Science and Technology hub
Polo Tecnologico di Pordenone - Science andTechnology hub
Consorzio Innova FVG - Science and Technology hub
Friuli Innovazione – Research and Technology
Transfer hub
BIC FVG S.r.l. – Enterprises incubator

Success story
VivaBioCell was founded in 2007 as a spinoff of University of Udine, Italy. The company
develops, manufactures and commercializes
automated bioreactors to support advanced
therapy medicinal product manufacturing forinnovative and regenerative medicine therapies
like autologous stem cell transplantation. To
do that, it has developed “Good Manufacturing
Practice – GMP in a box”, medical devices enabling
safe, efficacious, standardized and affordable
medical treatments by creating a next generation
tissue engineering manufacturing capability.
Current applications include developing stem
cell for the treatment of osteoarthritis as well
as bone regeneration for dental /maxillofacialreconstruction. This automated “GMP-in-a-Box”
system will be used to develop next generation
immune cells production in the treatment ofcancer trough natural killer cells.
In 2015 VivaBioCell was fully acquired by NantCell
Inc (based in Culver City, California), a subsidiaryof NantWorks LLC group, for about 60 million
dollars.

41

Lombardy
Infrastructures andconnections
 573 km of highways
 900 km of national roads 11,000 km of provincial roads 1,680 km of railway network—— International Airport
Gabriele D’Annunzio,
Brescia - Montichiari (120.5
km from Milan)
 Distance by car from Milan
to Paris (8h50min), Berlin(10h45min), Frankfurt(7h30min), Barcelona (10h) 4 International airports:—— Milano Malpensa Airport,
Varese - Ferno (54.5 km
from Milan)—— International Airport Il
Caravaggio, Bergamo Orio al Serio (60.4 km from
Milan)—— Enrico Forlanini Airport,
Milano - Linate (9.7 km
from Milan)

Industrial base
The Health industry is strongly
oriented to the future needs ofsociety, becoming an importantdriver to create or recognize new
emerging markets
In Lombardy Health Industry
contains a very rich and variedsystem of competences, which
includes the following themes:
 Biotechnologies: purebiotech companies researchand development of based
products exclusively on
biotechnologies
 Pharmaceuticals: thepharmaceutical industry
in Lombardy plays animportant role for the wellbeing and quality of life. A
role that combines the highpropensity to research and toinnovation with a significant
manufacturing activity

Contact info
Regione Lombardia – Team
AttrACT
www.regione.lombardia.it,
www.attractlombardy.it
investimenti.attract@regione.
lombardia.it+39 02 8515 5220
Marco Fedato

42

 Medical devices: it includes all
those medical technologies
that make the difference inmaking a healthcare system at
the forefront Food: related to foods withnutritional specificity forrehabilitation, nutraceuticals, etc
 Creative industries: related
to disability, maintenance,and design reacquisition of
psycho-physical faculties
 Constructions for equipped
living and working
environments and forindividual well-being systems

The Pharma sector is the mostadvanced in terms of technology
in Lombardy: companies invested
mostly in the Internet of Things,
3d printing, robotics and artificial
intelligence
The Biomedical enterprises arefocused on biomedical devices
for personal use, instrumental
use, electro medical use and forearly diagnostics
The priority themes oftechnological development are
e-health, new diagnostic systems,
drugs and innovative therapeuticpolicies, prevention, healthmonitoring, rehabilitation
The excellence of Lombardy Life
Sciences Cluster is characterized
by scientific and industrial
competencies in the: Biotechnology sector applied
to the health sector (redbiotech) GPET (Genomics, Proteomics
and Enabling Technologies)
sector Nano biotechnologies
 Pharmaceutical sector
and medical devices, withfocus on personalized
medicine (early diagnosis,
rehabilitation devices andothers) and mobile healthservices (telemedicine,
remote health monitoring andinteroperability platforms)
The Thematic Working Groups ofLombardy Life Sciences Cluster
are: PHARMACEUTICALS (newdrugs), MEDICAL DEVICES (fordiagnosis and therapies), ICT FOR
HEALTH, ADVANCED THERAPY(gene therapy, cell-based
products, combined therapies),
DIAGNOSTICS (in vivo, in vitro
and device diagnostics), andNEUROINFLAMMATION (researchof the pathogenetic mechanism
related to neuroinflammation inneurological diseases)

FACTS &FIGURES 1st Italian region in terms of employees in thepharma sector, with more than 30,000 units(47.2% at national level), of whom 2,825 deals
with R&D activities
 1st region in Italy for European funds obtainedin the health sector (4th among European
regions)
 With 28% of businesses and local units basedin Lombardy (162 units), 23% of investments
and 32% of the turnover, Lombardy is
confirmed the first region of Italy for presence,commitment and results in Biotech
 816 biomedical enterprises (307 with morethan 20 employees) and they employ 40% of
the Italian workforce of this sector
 Presence of Lombardy Life Science Clusterthat includes:—— 82 enterprises—— 24 Universities and Research bodies—— 20 Other bodies—— 6 Associations

R&D network
 The R&D investments of Lombard enterprisesin this sector accounts for roughly one third of
the national total Lombardy counts the highest
number of surgeries
 The research system consists of 6 Faculties ofMedicine, 2 Departments of Bioengineering, 28
hospitals with university course premises, 288
Research centers with research activities in thehealth sector and 186 centers with research lines
in non-food biotechnologies
 Public universities and Research centers involved
include LIUC, the Catholic University, Bicocca
University of Milan, the University of Milan, Vita
Salute S. Raffaele as well as the CNR and thePolitecnico of Milan Human Technopole (located at Expo Milano 2015site), the new Italian research centre that will be
an attractive hub for national and international
talents at European and global level forbiomedical research, genomics and for the futureof medical science

the financing
 The eligible projects must fall within one ofthese two categories: Company Development or
Relaunch of Productive Areas The intervention is dedicated to companies:
registered in the Italian Register of Companies
with an operating office in Lombardy at the timeof the supply of the contribution, active for atleast 24 months«INTRAPRENDO» Incentives for Startups
 The incentive consists of a zero-interest-rate loan
and a non-repayable grant (min €25,000 to max€65,000)
 The combination of the two can cover from 60%
to 65% of the total eligible cost (min €25,000
max €65,000) of the project The intervention is dedicated to:—— MSMEs active and registered in the Registerof Companies for no longer than 24 months,
with operating headquarter in Lombardy—— Individual entrepreneurs that have started
their own entrepreneurial activity for nolonger than 24 months
Thanks also to the ERDF - European Regional
Development Fund, Regione Lombardia allocatedin the 2014 – 2020 program period 36% of the fund(€349.2 M) to strengthen the research sector, foster
technological development and innovation. In thesame way, 30% of the fund (€294.6 M) is allocatedto promote the competitiveness of SMEs andimprove access to loans.

Sites and buildings
 AttrACT website www.attractlombardy.
it gives access to more than 100 investment
opportunities (greenfield and brownfield
opportunities), located in 55 Municipalities,
mapped out through the AttrACT Programme.
A variety of sites ranging from the officebuilding to the industrial facility. This initiative,
promoted by Regione Lombardia together
with Unioncamere Lombardia, is a uniqueexperimentation in Italy for the promotion of theinvestment opportunities located in Lombardy
 Within the Lombardy Life Science Cluster:
PARCO TECNOLOGICO PADANO (Lodi, LO) Within The Italian Scientific and TechnologicalParks Network:—— POLO TECNOLOGICO DI PAVIA (Pavia, PV)

Incentives and funding
Regione Lombardia supplies incentives forcorporate investments and Start-ups. For example:«AL VIA» Corporate Investments
 5% to 15% non-repayable grant for capital
expenditures in productive assets for a specificinvestment project Long-term financing from €50,000 to €2.85M at
favorable rates, with a duration from 3 to 6 years
 Free financial guarantee to cover up to 70% of—— COMONEXT (Lomazzo, CO)—— KILOMETRO ROSSO (Bergamo, BG)—— BERGAMO SVILUPPO (Bergamo – BG)
 “MIND” (Milano Innovation District) a worldleading science, technology and innovation park,a business friendly “innovation ecosystem” fordomestic and international players, a “catalyst”
for sustainable socio-economic growth, a new
vibrant community fully integrated with the city
centre of Milan. Located just a few miles NorthWest of the city centre, which hosted the sixmonth Universal Exposition in 2015.
43

Success story
SANOFI ITALIASANOFI is a French global
healthcare leader in the world.
With more than 100,000
employees present in 100
countries, the company has
79 manufacturing sites in 36
different countries. In 2017, thesales reached € 35bn.
SANOFI is one of the leading
pharmaceutical company in
Italy, where it has a strong
industrial presence. The Italiansubsidiary manufactures andmarkets drugs in all the group’sbusiness areas.
SANOFI Italia has its
headquarters in Milan andanother branch in Modena. In
Italy, there are 4 industrial plantsof SANOFI. A unit of clinicalresearch (CSU- Clinical Study
Unit) with 39 collaborators,
dedicated to conduct clinicalstudies operates at SANOFI sitein Milan.
The Lombardy site is an
example of positive growthwhich has been going on
for some time, thanks to an
investment plan of € 19 M overthe last three years enabling
to expand the production
capacity.

NOVARTIS FARMA
Novartis is a global healthcarecompany based in Switzerland
working in the pharmaceuticalsector. Second pharmaceuticalmultinational in the world by
turnover.
Novartis is present in Lombardy
with Alcon Italia SpA in Milanand Novartis Farma SpA or
Sandoz SpA in the province ofVarese.
Novartis is planning to increase
its investments in Italy. The
group’s investments will
be mainly allocate to R&D,
collaborating with research
centers and hospitals to carryout clinical trials, investing indata collection, training doctors
and supply advanced drugs.
In 2017 Novartis alreadyinvested € 61 M in Italy to
do 224 studies involving
10,000 patients. In Italy thegroup planned to launch aninvestment of € 200 M in R&D
in three years.

Business opportunity
AttrACT Program
The AttrACT Program is aunique innovative programin Italy: it brings together
investors, investment
opportunities and local
Municipalities thanks to a
dedicated online platform,
www.attractlombardy.it.
AttrACT aims at:
 developing the regional
offering
 promoting opportunities forinvestment
 bringing together the main
territorial stakeholders
More than 100 “ready to use”
investment opportunities,
representing all the 12
provinces of Lombardy andpertaining to 4 key segments:
Industry, Logistics, Offices
and Tourism. The Program has
mapped both publicly- andprivately-owned areas.
AttrACT sees the direct
engagement of the Lombardy
Municipalities involved in
the Program that are called
to identify local investment
opportunities (greenfield andbrownfield) in their area, madeit available to investors, andsimultaneously made commitments to simply
administrative processes, offer economic and tax
incentives and offer qualified assistance service.

MIND – Milano Innovation District

Commitments can vary according to theMunicipality:

The former Expo site will be transformed intoa “Science, Knowledge and Innovation Park“:
a hub open to the world, capable of attracting
international excellences and promoting Italiantechnology and culture in an extraordinary
location.

 Simplification of administrative processes suchas:—— Adopting the Action Plan by the city
council in less than 90 days from therequest—— Delivering a Planning Permission in lessthan 60 days from the request—— Dedicating a portal or an on line “front
office” service where investors can find all
useful information
 Economic and Tax incentivisation such as:—— Declaring in advance all urban planning andconstruction expenses without additional
expenses—— Offering reduction or exemption of
IMU, TASI, e/or TARI according to theMunicipality—— Reducing the primary and secondary landdevelopment expenses by at least 20%
 Promotion:—— Making available a support team thatcoordinates the work, facilitates therelationships and encourages collaboration—— Providing preliminary consulting services
and support to companies in thepresentation and implementation of theirprojects, with the issuance of written
opinions if requested in the proposal
AttrACT, where to invest in Lombardy.

An innovation, culture and research based identitywith international focus

A science and technology park with outstandingarchitectural features, able to attract investment
and generate economic benefits throughout
the country with scientific, recreational, cultural,
sports, residential, productive and tertiary
functions.
MIND will become a new part of the city: asmart, sustainable, authentic, inclusive and safe
community, able to attract talented people fromaround the world.
The three majors anchors of the project are: the new cross-disciplinary research
infrastructure Human Technopole which willdevelop personalized approaches in the fieldof medicine and nutrition on cancer andneurodegenerative diseases using genomics,
big data analysis and new diagnostics
techniques University of Milan Campus: a modern
scientific, education and research campus,
aiming to the most advanced international
standards for teaching, research andinteraction with the private industry
 Galeazzi research and treatment hospital:
gathering together the excellence in theorthopaedic field of IRCCS Galeazzi andthe experience gained in the cardiothoracovascular and bariatric field of the
Istituto Clinico Sant’Ambrogio, to offer patientsa great multi-specialized research hospital.

Piedmont
Infrastructures andconnections
Piedmont is located at theintersection of the two main axes
Lisbon-Kiev European Corridor
and Genoa-Rotterdam Corridor
24.
The region is a strategic point forgoods distribution in Europe with 3
logistics platforms - S.I.T.O (Turin),
C.I.M. (Novara), Interporto Rivalta
Scrivia (Tortona) - and a networkof about 1,000 km of motorways
and 2,000 km of railways. Its
position bordering Liguria makes
it the ideal rear logistics service
location for the port of Genoa (150km from Turin).

Contact info
Piemonte Agency
www.centroestero.org/en/
invest-in-piemonte.html
info@centroestero.org+39 011 6700511
Federico Zardi

46

Turin international airport :30
minutes from the city center.
Milan-Malpensa intercontinental
airport: 1 h from Turin.

Industrial base
In Italy, Life Sciences - specificallybiotechnology, pharmaceuticals
and medical devices – represent
one of the most promising
hi-tech industrial sector witha significant growth potential
in the medium to long term.
In Piedmont, the network of
research centres, multinational
companies and SMEs, is a clusterof innovation, education andtechnology transfer and is thecore of a strong, interlinked
system active in pharmaceuticals,
biotechnology, wellness andhealth massively supported byconverging technologies.
In particular, within thebiotechnology field, thetechnological vocation of
Piedmont’s R&D is in areas such ascell and molecular technologies,
molecular diagnostics andmolecular and traditional imaging.
The strong skills existing in
Piedmont in sectors such as ICT,
electronics and nanotechnologies(that are considered converging
technologies) have favoured thedevelopment of significant results
and expertise in bioinformatics,
diagnostics, data sciences andbiomedical equipment, micro
and nanotechnologies, strongly
fostering the innovation ecosystem
in interdisciplinary fields.
Among Piedmont’s leading key
players: Advanced Accelerator
Applications Srl (Aaa), Ephoran,
Huvepharma, Ab Sciex, Agilent
Technologies, Bracco Imaging,
Merck Serono, Sicor (Teva),
Diasorin, Delpharm, Ucb Pharma,
Sorin Biomedical, Olon, L’Oreal.

FACTS &FIGURES
LIFE SCIENCES CLUSTER
More than 400 companies
operating in the life sciences field
Over 250 companies specificallyin the healthcare and medtech
supply chain
2nd Italian region with 57
companies in the biotechnology
field
About 10k employees in 21
multinationals
21 multinationals in the life
sciences field
3 Public Universities
1 Science & technology park
dedicated to biotechnology:
Bioindustry Park Silvano Fumero
1 Innovation Hub for
biotechnology: bioPmed
820 research groups of which
60% in healthcare and medtech
fields scientific production
Privileged position:
Piedmont is at the centre of oneof the most dynamic biotech
areas in Europe. Its proximity
to other highly developed
European regions, such as
Lombardy in Italy, Rhône Alpes
in France and Geneva-Lausannein Switzerland is yet another plus
for widespread, synergic andshared development in the life
sciences and health sectors.

R&D network
Recent data confirm that Piedmont is a leading
Italian region in R&D. Companies expenditure in
R&D: 1.42% of GDP (national average of 0.65%),
with a number of workers in R&D of 6.2 per 1,000
inhabitants (national average of 4.0) and anincreasing IP impact, with a number of 137.6 patents
registered per million inhabitants (national averageof 83.6) (Source: Istat 2017).

Piemonte Health & Wellness: is a special project
promoted by the Regione Piemonte, financed by
ERDF – European Regional Development Fund andmanaged by the Piemonte Agency.

 200 private and public R&D centres, 7 Innovation
Hubs, 4 Science &Technology Parks

The project provides international players with apreferential channel to meet and develop businesswith over 100 top class selected local companies,
active in the medical, wellness and cosmetics
sectors. Assistance is given free of charge: from theidentification of international players’ outsourcing
needs to the arrangement of B2B meetings with themost suitable partners and visits to local companies.

 1st Italian region in terms of private investment in
R&D

The project Team’s assistance is supply chain
focused and completely free of charge.

 3rd Italian region for hi-tech patents

For more information: lifesciences@
centroestero,org,

Incentives and funding
Regione Piemonte has allocated € 1 bn to promote
the growth and competitiveness of the wholeterritory. The Region’s industrial policy aims
to achieve 3 main objectives: to maintain andenhance the existing industrial activities, to expand
investments of the companies already active on
the territory, to attract new businesses wanting
to realise innovation and industrial development
projects.
Funding is provided for: setting up andstrengthening labs and research centres; creating
and developing start-ups; technology transferfrom research to SMEs through Innovation Hubs;
collaborative research on major challenges throughTechnological Platforms: Intelligent Factory, Life
Sciences, Bioeconomics, Aerospace, Automotive;
supporting industrialisation of research results (IR2Call), through relevant investment programs aimed
at industrializing the results of R&D activities alreadypartially acquired.
The subsidy system in Piedmont focuses on both thestart-up of new initiatives and on the developmentof existing companies. Subsidies to companies cantake the form of soft loans, non-repayable grants or
free-of-charge guarantee support (in compliancewith the European regulation on state aid) and canvary according to the type of beneficiary, the kind ofinvestment and the nature of expenses.

Sites and buildingswww.centroestero.org/en/key-sectors/scienze-dellavita.html

Business opportunity
The new Teaching and Research Hospital is a
project of strategic international relevance for thelife sciences and health sectors that will further
cast Piedmont on the global community scene.
The project foresees high quality care andteaching integrated with the healthcare system.
There will be 4 functional centres, all closelyinterconnected and served by private parking,underground and a multi-store car park:
1.

Healthcare and Clinical Training Centre: anarea of 127,000 m2, of which 5,000 m2 arededicated to clinical training, and a total
capacity of 1,040 beds

2. Research centre: an area of 10,000 m2
designed for about 1,000 people and sharedby teachers, assistants, doctoral students andauxiliary staff
3. Teaching centre: an area of 31,000 m2
designated for one-cycle master degree
programs, three-year degree courses andspecialist degree courses in medicine or healthprofessions for a total of 5,000 students
4. Residential centre: an area of 8,000 m2
offering short-term accommodation for
temporary guests working or involved in
activities in one of the centres (190 places)
and for the discharged patients that still need
temporary low-intensity care (30 places)

Innovation hub – BIOPMED is the Innovation Hubfor Biotechnology dedicated to healthcare related
products and services. It was established in 2009by Regione Piemonte and has since grown into
a community of about 400 members including
companies, research centres, universities andfoundations.
25 m€ of regional co-funding collected; over
100 training events organized; over 20 strategic
agreements for international cooperation;16
European projects activated; 60 R&D projects
completed; 3 major international B2B events
organized: EuroMedTech, BioEurope and Meet in
Italy for Life Science.
47

5.

Trentino
Infrastructures andconnections
 Airports: 45 minutes from
Verona airport (Catullo) Main Highway: A22 BrenneroModena Railway that connects North
East of Italy with Austria andGermany

 Within 2-3 hours flight frommajor European cities

HEALTHCARE CLUSTER

Industrial baseIndustrial Know-how: Brenner Basistunnel inconstruction

Medical devices, pharmaceuticaland food supplements, diagnostic
applications, biomedical
engineering, biomolecular andmicrobiological investigation.

 Interporto of Trento

Main companies:

 Broadband with more than
1,100 km of optical fiber

ePharma, Novartis-Sandoz,
Biomat, Biodermol, Eurocoating,
Novagenit, Corehab, OPT
SurgiSystems, Bio4Dreams, GPI,
Imagina Biotech, Microbion,
Wondergene.

 Proximity to key European
countries (Switzerland,
Germany, Austria)

FACTS &FIGURES Export: 106 million euros
 40 companies
 5th Region for turnover
generated 20 million € invested in R&D
by the Public Sector
 1.5 million € for R&D on
digital Healthcare
400 researchers, 200 employees
Foreign companies:
 Novartis-Sandoz
 OPT SurgiSystems
Specialization areas: eHealthR&D network

 Medical devices

Research Centers: Bruno Kessler
Foundation (ICT, microsystems,
smart materials), Edmund Mach
Foundation (agrifood, genomics,
environment), Trento University.

 Biology

Trentino Salute 4.0 is the first
Competence Center in Italy
focused on digital healthcare
between the Healtcare Institution,
FBK and the Autonomous
Province of Trento.

Contact info
Trentino Sviluppo SpA
www.investintrentino.it
info@investintrentino.it+39 0464 443111
Monica Carotta
Massimo Zorzi
Romina Falagiarda
Francesca Azzolini

48

Labs: LaBSSAH – Laboratory
od Biomolecular Sequence andStructure Analysis for Health,
CIBIO – Centre for Integrative
Biology, Neuroinformatics
Lab, Ausilia – Assisted Unit for
Simulating Indipendent Living
Activities, CimeC - Center for
Computational and System
Biology, Proton Therapy Center.
Know-how: Personalized medicine andeHealth devices
 Genetics and biomarkers
 Brain and neuronal Rehabilitation and accessibility
 Computational models

 Rehabilitation

Incentives and funding

Business opportunity Up to 80% local grant on R&D project Trentino Sviluppo, in-house company ofthe local Government, has 6 BIC (Business
Innovation Centre) Up to 70% local grant on internationalization
 Up to 60% local grant for researchers hiring
 Up to 50% local grant on innovation
 Private – Public equity financing up to 1.5 million €Sites and buildings
B.I.C. Trentino Sviluppo: 6 Business Innovation
Centres in the province of Trento.
Dedicated spaces for biotech industries at CIBIO
and FBK.

 We provide: fully equipped spaces andinfrastructures, support on technology
transfer, technology partnership, supply chain
development, HR selection, incentive selection
 Significant local incentives, efficient andreliable autonomous government, 1st in Italyfor quality of life, supportive R&D environment,
0 local tax (for 5 years), a workforce you cancount on Provide Equity through Trentino Invest, theTrentino public/private investment company

Formulas: pre-incubation (Start Ups), incubation(SME), accelerator programs (BIO4 Dream).

Success story
Eurocoating was founded in 1990 by the company
Centro Sviluppo Materiali to follow up on the
research of new materials undertaken at the
Pergine Valsugana site. In 1998 it was acquiredby Biocoating, active in the biomedical field, andbegan the production of coatings and surface
treatments on third party medical devices.
Coatings are mainly applied to orthopedic
prostheses and dental implants, using plasma
spray technologies (APS and VPS), both intitanium and in hydroxyapatite.
Established in the Pergine Valsugana Business
Innovation Center since 2006, and specialized
in the 3D printing technology (additive
manufacturing) of titanium metal components,
Eurocoating started the research activity in this
sector well in advance of the current explosionof the market. Thanks to the advantage gained,
the company is now industry leader and it isconsidered one of the biggest multinational
companies globally, to support the largest
production of innovative prosthetics that has everbeen realized with this technology.
Eurocoating has requested and obtained new
additional spaces to support the current businessdevelopment phase and to continue the research
activities necessary to maintain the competitive
advantage gained. It will therefore have 1,340
square meters available, compared to the current
560 square meters. In 2015, Eurocoating’s turnoveramounted to 21 million euros and at the end of2017 raised up to 25 million euros. Thanks to theagreement signed with Trentino Sviluppo for the
expansion in the Pergine BIC, the company will
increase from the current 127 employees to 150
workers, guaranteed until 2019.

49

Tuscany
Infrastructures andconnections
 2 integrated international
airports (Florence and Pisa),
serving over 50 international
destinations

with Southern Italy and Malta
 1 main commercial port
(Livorno) with direct links to
the 10 major Mediterraneanports 3 main logistic parks (Livorno,
Prato and Arezzo) 1:30h from Florence to Romeby high-speed train

7.5% Regional GDP

Industrial base

Tuscany is crossed by:

Leading region in R&D:
Tuscany is one of the world
leading regions in terms ofresearch in vaccines, oncology,
cardiovascular, neurology,biorobotics & biomaterials (oneof the most recent vaccines,
anti-meningococcus B has beendeveloped in Tuscany – Novartis– GSK)

 the EU “ScandinavianMediterranean Core Network
Corridor” linking the Baltic Sea

First class public health systemwith high expertise in all thefields of medicine, operatingwith cutting edge procedures forclinical trials
Synergy between public andprivate research thanks to a welldeveloped technology transfer
model all around Tuscany: 4 business incubators for life
sciences based companies
 Tuscany Life Sciences Cluster(that counts more than 300
affiliated companies, 19,000
employees , 823 patents)

Contact info
Regione Toscana - Invest in
Tuscany
www.investintuscany.com
info@investintuscany.com
T +39 055 4385643
Filippo Giabbani

50

370 firms in Life Sciences(42 pharma, 80 biotech, 120
medical devices and 128
software&services)
Turnover: EUR 8 billion 1:40h from Florence to Milan
by high-speed train
 the major Italian highway (A1)connecting Milan with Romeand Naples

FACTS &FIGURESMany international companies
have set up their headquarters
for Italy and Southern Europe in
Tuscany (Eli Lilly, Kedrion… ) andmany international companies
have set up in Tuscany local units
for manufacturing products,
organizing clinical studies withdomestic partner (Biomérieux,
Novartis – GSK)

19,000 employees (= 1.2% of
total Tuscany’s employees)
2,000 employees in R&D
activities
1.45 bln € export (=18% of LS
Turnover)3 Universities involved in LS
R&D, with a total of 19,000
students in scientific fields
Main Research areas in
LifeScience in Tuscany
1.

Pharma (Advanced
Therapy - Antibodies Blood Factors - Growth
Factors - Cytokines- Drug Development Immunotherapies - Pharma
production - Antitumor
compounds - Developmentof anti-parasitic and antiviral
agents - Orphan diseases)

2. Software (Bioinformatics- Communication systems- eHealth - Telemedicine- Telematics - Telemetry- Image Analysis - IT
infrastructures - Mobile
App)
3. Biotechnology (Genomic
search for new diagnostics- Protein atom depth
analysis)

R&D network
3 major Universities (Florence, Siena and Pisa)
2 Superior Graduate School (SSSA - Scuola
Superiore Sant’Anna, SSNP – Scuola Normale di
Pisa)
Advanced Institutes (IMT - Institute for Advanced
Studies of Lucca, SUM – Italian Institute of Human
Sciences, in Florence)
3 National Research Centres
 National Institute for Nuclear Physics (INFN) National Institute for Astrophisics (INAF)
 National Research Center (CNR), present in
Tuscany with 19 Institutes of Research

Incentives and funding
For detailed information please visit
www.investintuscany.com/incentives

Sites and buildings
 4 business incubators for life sciences based
companies
 Tuscany Life Sciences Cluster (that counts
more than 300 affiliated companies, 19,000
employees, 823 patents)

logistical platform to support the industries
operating in the life sciences sector, which will
make it possible to optimise the distribution
chain of medicines produced in Tuscany, andmore generally in central Italy. The investment
is aimed at equipping an area of 125,000 square
meters, half of which will be built, to build 21,000
square meters of warehouses, with temperaturecontrolled environments, suitable for the storageof pharmaceutical products, with 8 loading areas
and as many intended for the shipment of goods,
as well as about 6,000 square meters of offices.
It is a platform designed to have high expansion
capacity, to serve any other interested companies
in the many areas of life sciences, as newwarehouses can be built for an additional 20,000
square meters of floor space.
The storage capacity, from a pre-feasibility
analysis, is estimated at 38,000 initial pallet
places, three quarters of which can holdtemperatures between 15° and 25° and one
quarter between 2° and 8°.
70% of stocks will be for raw materials andpackaging, 30% for finished products, which will
be handled at a rate of 52,000 pallets per year.
80% are destined for export and 20% for thedomestic market.
M&A IN COMPANY OPERATING IN MEDICALIMAGING AND ULTRASOUND TECHNOLOGIES
Brownfield Project
Investors: Financial or Industrial operating inpharma/medical device sector
Value of total Investment: to be defined

Success story

Proposing Companies: Local firm searching forstrategic partnership

1.

Core business: the company, born as a Spin-Off
company of the Italian National Research Counciland University of Pisa, is specialized in Medical
Imaging and Innovative Ultrasound Technologies.
The company produces its Cardiovascular Suite, a
CE marked medical device software for assessing
early markers of cardiovascular risk. The company
aims to design a next generation of biomedical
ultrasound systems.

In 2018 Yf Capital, a Chinese private equity
fund co-founded by Jack Ma, acquired 100% of
the ESAOTE group, a leader in the biomedical
sector present in Florence with a plant that
employs 220 workers

2. In 2018 the Swiss multinational Lonza, activein the biopharmaceutical sector, has decided
to invest in the Sienese startup Exosomics,
which develops non-invasive liquid tests for thescreening and diagnosis of cancers in the initialphase
3. In 2017 The Swiss pharmaceutical group Skan
has invested 6 million euros in the Sienesestartup Pharma Integration, which specializes
in the development of fully robotic systems
and production lines for filling syringes andbottles for vaccines and oncological products

Business opportunity
PHARMA AND MED TECH LOGISTIC ANDDIGITAL HUB

Assets:Commercial distribution on the global market
based on 14 distributors and 8 agents monitoring
the system and focused on medical devices sales.
Synergies and collaborations with the Italian
National Research Council CNR, the University of
Pisa and several research institutes at global level.
Strong scientific references on the products usage
validating the system.
The Cardiovascular Suite is CE marked and thecompany got the ISO 9001:2008 certification.
High market’s recognition and high investments
budget ratio.

Greenfield Project
Investors: Financial or Industrial operating inpharma sector
Proposing Companies: 4 Pharma companies
already operating in Tuscany
Description: the possibility of investing in a digital
51

www.investinitaly.com

REGIONE PUGLIAForeign Direct Investment Department
Via Liszt, 21 - 00144 Rome, Italy
fdi@ice.it
www.ice.it
www.investinitaly.com